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SUMMARY 
Variations of the isoform 3 expression of the sodium / calcium exchanger play an 
important role in the response to neuronal damage after an ischemic insult. I found 
that the transcription factor (GATA binding protein) 3 GATA3 activates the 
transcription of ncx3 in rat cortical cultures. In fact, the overexpression of GATA3, 
obtained as a result of transient transfection of the plasmid containing the GATA3 
cDNA in neurons, leads to a significant increase in the luciferase activity of the ncx3 
promoter, in parallel with an increase in mRNA and protein expression of ncx3. In 
contrast, the transfection of a siRNA capable of reducing the protein expression of 
GATA3 by about 60% causes a reduction of the luciferase activity of the ncx3 
promoter and a decrease in the ncx3 mRNA. The site-specific mutagenesis of the 
binding sequence of GATA3 on the ncx3 promoter demonstrates that the mechanism 
by which GATA3 activates NCX3 is site-specific. More important, in vivo, GATA3 
recruitment to the ncx3 gene was increased in the temporoparietal cortex of rats 
subjected to Preconditioning (PC) followed by transient middle cerebral artery 
occlusion (tMCAO), with an increase of histone 3 lysine 3 trimethylation of the ncx3 
promoter region. Interestingly, in the same experimental conditions histone 
acetylation on ncx3 promoter was unmodified. Furthermore, Re-ChIP experiments 
demonstrated that GATA3 forms a functional complex with the histone lysine methyl 
transferase KMT2A on the ncx3 gene during PC+tMCAO. Therefore, increasing 
KMT2A expression or activity might represent a new possible strategy in stroke 
intervention. 
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I. INTRODUCTION 
I.A. ISCHEMIC PRECONDITIONING IN BRAIN 
Brain ischemia is one of the most common causes of death and the leading cause of 
adult disability in the world. Brain ischemic preconditioning (BIP) refers to a transient, 
sublethal ischemia which results in tolerance to later, otherwise lethal, cerebral 
ischemia. neuroprotective mechanisms may involve a series of molecular regulatory 
pathways. Generally speaking, any stimulus capable of causing injury to a tissue or 
organ can, when applied close to (but below) the threshold of damage, activate 
endogenous protective mechanisms and thus potentially lessen the impact of a 
subsequent, more severe attack. a phenomenon known as ischemic preconditioning 
(IP) or ischemic tolerance (IT)(Liu et al. 2009). The terms 'tolerance' and 
'preconditioning' were introduced for the first time by Janoff in 1964 (JANOFF 1964) 
ischemic preconditioning is an adaptive reaction to a potentially noxious stimulus, 
such as ischemia, hypoxia, hypoglycemia, or inflammation(Liu, Sheng et al. 2009) 
.The phenomenon of ischemic preconditioning has been observed in numerous 
organs such as brain (Kitagawa et al. 1991) and heart (Meldrum et al. 1997), as well 
as in a wide range of species like the gerbil (Kirino et al. 1991), the rat and the 
mouse. Various brain regions, hippocampus, cerebral cortex, basal ganglia and 
thalamus were often reported to acquire ischemic tolerance (Kitagawa, Matsumoto et 
al. 1991) The brain is one of the most sensitive organs to injury. A constant flow of 
blood to the brain is essential for delivering oxygen and glucose to neurons. If this 
flow is disrupted for even a short period of time, the result is cell damage or death. 
Neurons are rarely replaced once they have died, so the damage to affected regions 
may be permanent (Caplan 2000). there are two threshold values for cerebral blood 
flow. Reduction in blood flow below the first threshold results in electrical failure 
within neurons, and further reduction in blood flow below the second threshold leads 
to the failure of metabolism and ion pumps. Cells with lower perfusion than the 
second threshold are designated to die. Between the two thresholds, cells are 
electrically silent but maintain a low level of metabolic activity and can be stable for 
hours. If normal blood flow is restored within a reasonable amount of time, they may 
recover with no apparent damage. Longer periods of ischemia, however, will result in 
their death. So these cells have a variable fate, and constitute what is known as the 
ischemic penumbra.(Dirnagl et al. 1999) It is the cells within the penumbra that 
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receive the most benefit from ischemic preconditioning endogenous neuroprotective 
mechanisms and potentially, a window of opportunity to utilize these mechanisms in 
the clinic to treat patients with stroke and other CNS disorders.(Liu, Sheng et al. 
2009) 
 
I.A.1. Mechanisms of Brain Ischemic Preconditioning 
Two temporally distinct types of ischemic tolerance are afforded by sublethal 
pretreatment: early and delayed tolerance (Bhuiyan and Kim 2010),The first phase, 
named rapid or acute preconditioning ,starts 3–5min after the preconditioning 
Stimulus and ends 1h later and is due to rapid post-translational Protein 
modifications .The second phase, named delayed preconditioning ,starts2–3days 
after preconditioning And ends 1week later and mainly involves de novo protein 
synthesis (Cuomo et al. 2015).To induce tolerance by means of ischemic episodes, 
three factors should be considered: 1) the duration, 2) the time interval, and 3) the 
number of episodes. First, the preconditioning stimuli must be severe enough to 
initiate a response, but not so severe as to cause permanent damage. Second, some 
interval of time must exist between sublethal and lethal stress. Third, the number of 
short ischemic episodes should be considered for sufficient stimulation of the 
protective response against a lethal ischemic insult. In general, the process of 
tolerance induction can be divided into the following elements: sensors of the stress 
signal, transducers of the stimulus, and effectors of the tolerance. First, the 
preconditioning stimulus must be recognized by cellular sensors so that the cells can 
be prepared for upcoming stress. Neurotransmitter and cytokine receptors, ion 
channels and redox-sensitive enzymes generally work as molecular sensor of stress 
stimuli. These sensors activate enzymes, such as kinase protein Ras, Raf, mitogen-
activated protein kinase (MAPK) kinase (MEK), extracellular regulated kinase (ERK), 
Akt, and protein kinase C, and signaling molecules, such as nitric oxide (NO), 
diacylglycerol, inositol triphosphate, Ca2+, and ceramide, which transduce the signal 
and initiate an adaptive response. Finally, effectors of the preconditioning response 
confer tolerance to cells or tissues through anti-excitotoxicity, anti-apoptosis, anti-
inflammation, protection of mitochondria and increased anti-oxidant mechanisms 
(Bhuiyan and Kim 2010). Ischemic tolerance thus reflects a fundamental change in 
the cellular response to injury that shifts the outcome from cell death to cell survival 
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(Dirnagl et al. 2003). Although transcription factors, such as HIF-1, CREB and NF-κB 
are already known to be driving neuroprotective gene expression upon an ischemic 
preconditioning stimulus, we are today more aware that apart from the transcription 
factors and DNA sequence, regulation of such transcriptional activity requires the 
cooperation of a third party, namely epigenetic alterations of the DNA and histones. 
Indeed, these modifications crucially regulate the accessibility of specific regulatory 
DNA elements for transcription machinery yet involvement of these mechanisms in 
brain ischemic preconditioning and neuroprotection is mostly unknown. 
 
I.A.2. Clinical Applications and Future Prospective  
The preconditioning phenomenon has been successful as an experimental procedure 
for identifying the mechanisms responsible for brain protection and regeneration. 
Important examples of strategies to modulate these mechanisms include 
erythropoietin, activators of mitochondrial KATP channels, and volatile anesthetics. 
The phenomenon of ischemic tolerance has not only been found in cells, organs and 
animal experimental models; some clinical observational data indicate that this 
phenomenon may occur naturally in the human brain in the form of short episodes of 
ischemia without infarction, known as TIA. In a retrospective clinical study, evaluated 
148 stroke patients with and without antecedent TIA and found that TIA before stroke 
is associated with significantly less severe stroke on admission and improved 
outcomes on follow-up. Another retrospective study, which included more than 2000 
patients, confirmed these results 1 year later . In support of these findings, studies 
using magnetic resonance imaging and neuroradiological analysis showed that 
ischemic stroke patients with prodromal TIA have significantly smaller ischemic 
lesions after stroke than those patients without TIA . These observations suggest that 
endogenous preconditioning triggered by TIA is present in the human brain. Induction 
of ischemic tolerance in the brain has been suggested to be a promising clinical 
strategy for preparing the brain for situations of possible ischemia, such as cardiac or 
brain surgery and in patients with a high risk of stroke. However, because of ethical 
and safety concerns associated with ischemic preconditioning, researchers are trying 
to identify a safer preconditioning stimulus that would be both practical and effective 
or a biological agent that can mimic preconditioning pharmacologically. Many 
candidate pharmacological regulators of the stress response and inducers of 
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ischemic tolerance have been proposed, one of which is erythropoietin. 
Erythropoietin is approved for the treatment of anemia and seems safe and effective 
for critically ill patients who are anemic and have experienced trauma. The iron 
chelator desferrioxamine is clinically approved for various indications, including 
thalassemia and other iron-overload syndromes. Various inhalational anesthetics 
used in human beings (e.g., sevoflurane) induce tolerance against brain ischemia 
and act as brain protectants after ischemia in preclinical experiments. These 
compounds are safe and effective at eliciting early preconditioning in patients 
undergoing coronary artery bypass graft surgery in randomized controlled trials. 
These drugs also elicit delayed preconditioning in human beings. Another promising 
approach is remote preconditioning in which preconditioning of one organ or system 
leads to protection of a different (remote) organ. The prototypical approach for 
remote preconditioning is the initiation of short ischemic insult(s) to a limb to protect 
organs such as the heart and the brain. Remote preconditioning might indicate a 
crosstalk between the brain and the rest of the body in response to stress through 
the peripheral nervous system or paracrine signal. Randomized clinical trials have 
already shown the efficacy of this strategy for the heart. Remote preconditioning is a 
particularly attractive strategy for protecting organs that are highly susceptible to 
damage but that are difficult to target, such as the brain. Although many researchers 
are actively characterizing the signaling mechanisms of ischemic preconditioning in 
the nervous system, our knowledge of cerebral ischemic tolerance is still in its infancy 
and insufficient to be able to translate the laboratory results into application. Many 
issues need to be resolved to avoid disappointing results from the clinical application 
of ischemic preconditioning, e.g., whether the tolerant state can be maintained long 
term and provide chronic neuroprotection. Thus far, it appears that ischemic 
tolerance persists for approximately 1 week in the brain. The threshold for tolerance 
induction and for cell injury needs to be determined. Pharmacological substances 
used for tolerance induction need to be safe. In conclusion, the past two decades 
have provided interesting insights into the mechanisms and potential applications of 
ischemic tolerance in the brain. Current knowledge suggests that the preconditioning 
strategy and related interventions, such as remote preconditioning and 
pharmacological preconditioning, can protect neurons and improve neuronal survival 
after critical ischemia, and, thus, have promise for practical application in cases of 
vascular neurosurgery and endo-vascular therapy and possibly in the management 
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of brain trauma. As knowledge in this field advances, the unresolved issues 
concerning the preconditioning cascade will likely be resolved and will lead to 
pharmacological strategies for protecting the brain from ischemic injury, traumatic 
brain injury, and other neurodegenerative disorders.(Bhuiyan and Kim 2010). 
 
I.B. EPIGENETICS 
Conrad Waddington introduced the term epigenetics in the early 1940s.He defined 
epigenetics as the branch of biology which studies the causal interactions between 
genes and their products which bring the phenotype into being. In the original sense 
of this definition, epigenetics referred to all molecular pathways modulating the 
expression of a genotype into a particular phenotype. Epigenetics is generally 
accepted as ‘‘the study of changes in gene function that are mitotically and/or 
meiotically heritable and that do not entail a change in DNA sequence. "In particular 
the epigenetic modifications described in current literature generally comprise histone 
variants, posttranslational modifications of amino acids on the amino-terminal tail of 
histones, and covalent modifications of DNA bases.(Dupont et al. 2009) 
I.B.1. Nucleosome 
Chromatin is the complex of DNA wrapped around histonic proteins found in the 
eukaryotic nuclei. The functional unit of chromatin is the nucleosome. Nucleosomes 
elicit an initial ~7-fold linear compaction of genomic DNA. They provide a critical 
mechanism for stable repression of genes and other DNA-dependent activities by 
restricting binding of trans-acting factors to cognate DNA sequences. They are 
engineered to be nearly meta-stable and disassembled (and reassembled) in a facile 
manner to allow rapid access to the underlying DNA during processes such as 
transcription, replication and DNA repair. Nucleosomes protect the genome from 
DNA damaging agents and provide a lattice onto which a myriad of epigenetic 
signals are deposited. Moreover, vast strings of nucleosomes provide a framework 
for assembly of the chromatin fiber and higher-order chromatin structures. (Figure 1-
A). Nucleosomes constitute the basic repeating subunit of chromatin. Each 
nucleosome can be considered as composed of a nucleosome ‘core’, linker DNA, 
and in most instances, a linker histone. The structure of the nucleosome core 
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includes a 147 bp segment of DNA and two copies each of four core histone proteins 
(H2A, H2B, H3 and H4).The core histones assemble into a spool-like structure onto 
which the core DNA is wrapped, in about 1¾ left-handed superhelical turns, forming 
a squat disc-like structure about 5.5 nm in height and 11 nm in diameter .The core 
DNA is in tight association with the core histones and is protected from nuclease 
digestion whereas the linker DNA is rapidly digested.(Cutter and Hayes 2015). 
Histones, enriched in basic amino acids, are proteins which structure is made of a 
globular domain and an N- terminal tail protruding from the nucleosome. Although the 
histones are classified among the most evolutionarily conserved proteins, they 
represent the most variable in terms of posttranslational modifications.The N- 
terminal tails of histones are usually targets for various covalent posttranslational 
modifications, including acetylation, phosphorylation,methylation, sumoylation and 
ubiquitination (Figure 1). The specific combinations in posttranslational modifications 
generate a sort of “histone code”. The role of these modifications is found in their 
particular combinatorial pattern since they decode for a selective chromatin affinity to 
the associated proteins, which determine whether the chromatin is active (relaxed 
state) or silent (condensed state) (Thiagalingam et al. 2003).Thus, histone code 
influences the structure and pattern of chromatin condensation and consequently it 
has been found involved in the gene regulation (Jenuwein and Allis 2001). 
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    Figure 1. Chromatine organization into nucleosomes (A) and epigenetic modifications (B). 
 
 
I.B.2. Epigenetic Modifications 
Two types of chromatin modification that regulate transcription of the protein-
encoding genome are listed in (Figure2). These modifications have been broadly 
classified into repressing and activating — in other words, they correlate with, and 
perhaps directly regulate, gene repression and induction. DNA methylation occurs at 
cytosine residues usually within CG dinucleotides or CNG trinucleotides, and 
generally opposes transcription. DNA hypermethylation is a feature of certain human 
cancers, causing aberrant repression of tumour suppressor genes through 
methylation of the CpG islands in promoters. There are various histone PTMs, 
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including acetylation, phosphorylation, methylation, ubiquitylation and SUMOylation. 
These modifications decorate the canonical histones (H2A, H2B, H3 and H4), as well 
as variant histones (such as H3.1, H3.3 and HTZ.1). Most modifications localize to 
the amino- and carboxy-terminal histone tails, and a few localize to the histone 
globular domains. Lysine is a key substrate residue in histone biochemistry, because 
it undergoes many exclusive modifications, including acetylation, methylation, 
ubiquitylation and SUMOylation. Acetylation and methylation involve small chemical 
groups, whereas ubiquitylation and SUMOylation add large moieties, owing to their 
bulk, may lead to more profound changes in chromatin structure. Another degree of 
complexity is that methylation can occur several times (mono-, di- or trimethylation) 
on one lysine side chain, and each level of modification can have different biological 
outcomes. For example, there is abundant evidence that acetylation is activating, 
whereas SUMOylation seems to be repressing, and these two types of modification 
may mutually interfere. By contrast, methylation and ubiquitylation have variable 
effects, depending on the precise residues and contexts. For example, trimethylation 
of lysine 4 in histone H3 (H3K4me3) occurs at the 5ʹ ends of ORFs as genes 
become induced, whereas H3K9me3 occurs in compact pericentromeric 
heterochromatin, which is transcriptionally inert. In H3 and H4, arginine residues can 
also be mono- or dimethylated, and in the latter case the methyl groups can be 
placed symmetrically or asymmetrically on the side chain. Arginine methylation 
seems to be strictly activating to transcription Serine/threonine phosphorylation is 
also involved in transcription. All histone PTMs are removable. Histone deacetylases 
(HDACs) remove acetyl groups and Ser/Thr phosphatases remove phosphate 
groups. Ubiquitin proteases remove mono-ubiquitin from H2B. Arginine methylation is 
altered by deiminases, which convert the side chain to citrulline. Two classes of 
lysine demethylase have recently been identified: the LSD1/BHC110 class (which 
removes H3K4me1 and me2) and the jumonji class (which removes H3K4me2 and 
me3, H3K9me2 and me3, and H3K36me2 and me3). This finding put an end to 
heated debate about the reversibility of histone lysine methylation and whether it is 
the only ‘true’ epigenetic histone PTM. As mentioned above, the functional 
consequences of histone PTMs can be direct, causing structural changes to 
chromatin, or indirect, acting through the recruitment of effector proteins. In addition 
to the idea that histone PTMs directly alter nucleosome fibre structure is an 
expanding body of evidence that histone PTMs serve as binding surfaces for the 
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association of effector proteins. The initial finding was for acetyl lysine, which has 
been shown to associate with bromodomains. In this case, acetylated H3 stabilizes 
binding of the histone acetyltransferase GCN5 through its bromodomain14. Lysine 
methylation provides an important switch for binding of representatives of the ‘royal 
family’ of domains, including chromodomains and tudordomains. (Berger 2007) 
  
 
   Figure2 Chromatin modifications art the complex language of chromatin  
 
I.B.3. Histone Lisine Methilation and Histone Lisine Demethylation 
The enzymes involved in lysine methylation were first found to target histone and 
thus were initially named histone methyltransferases and histone demethylases, 
following the naming model for histone acetyltransferase and histone deacetylase. 
With accumulating evidence that these modifications are not histone specific, a new 
nomenclature has been advocated for more generic names for these enzymes . The 
enzymes that add or remove the methylation mark on lysine residues are now named 
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lysine methyltransferases (KMTs) and lysine demethylases (KDMs).(Zhang et al. 
2012). The SET domain is a 130 amino acid catalytic domain initially found to be 
conserved in Su(var)3-9, E(z) (enhancer of zeste) and trithorax. SET domain-
containing enzymes are currently the larger of the two classes of KMTs. The second 
class of KMTs is represented solely by KMT4 (also known as Dot1p in yeast and 
Dot1L in human), which does not have a SET domain. Even though the catalytic 
domains of these two enzyme classes are distinct, both use S-adenosyl-Lmethionine 
(SAM) as the methyl group donor (Figure 3B). KMTs observe a high degree of 
enzymatic specificity for the lysine within the substrate and for the degree of 
methylation (Figure 3C). Therefore, KMTs can be highly specific, but their interacting 
partners can alter their target lysine or degree of activity. the first histone KDM, 
LSD1/KDM1A (Figure 3A and Table 1), as part of the C-terminal binding protein 1 
(CtBP1) corepressor complex. KDM1A was found to be associated with other similar 
corepressor complexes, suggesting that this protein was a candidate repressor. 
KDM1A contains a flavin adenine dinucleotide (FAD)-dependent amine oxidase 
domain that demethylates H3K4me2 and H3K4me1 and modulates gene expression 
(Figures 3B and 3C). Subsequent to the discovery of KDM1A, an additional class of 
KDMs was discovered. This enzyme class utilizes the JmjC domain (Figures 3A and 
3C) to catalyze demethylation through the oxidation of methyl groups. JmjC proteins 
rely on α- ketoglutarate, molecular oxygen, and Fe(II) as cofactors for demethylation 
(Figure 3B). In some cases, the JmjN domain is observed with the JmjC domain and 
is essential for enzymatic activity. The KDM2 and KDM3 families were unable to 
demethylate trimethylated lysines; however, this lack of activity was remedied by the 
discovery of the first tri-demethylase family, KDM4AKDM4D (also known as JMJD2A-
JMJD2D) (Figure3A). KDM4A-KDM4D remove H3K9me3/H3K9me2, 
H3K36me3/H3K36me2, and H1.4K26me3/H1.4K26me2, but are unable to remove 
H3K9me1 or H3K36me1, emphasizing the specificity for both the site and degree of 
methylation. Subsequent to these discoveries, a multitude of groups proceeded to 
identify additional amine oxidase- and JmjC-containing KDMs (Figure 3C). However, 
no enzyme that is capable of demethylating H4K20me3 or H3K79me1/ 
H3K79me2/H3K79me3 has been discovered. Recently, LOXL2 has been 
demonstrated to remove methyl groups by deaminating lysine. Therefore, we 
hypothesize that LOXL2 or other LOX family members may catalyze demethylation of 
H4K20me3 or H3K79, which is an exciting area for future research (Black et al. 
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2012). Unlike acetylation, where positive charges on histones are removed, relaxing 
chromatin and activating genes, methylation or its removal does not affect charges 
on histones. Histone lysine residues can be monomethylated, dimethylated, or 
trimethylated (Bannister and Kouzarides 2004), while arginine residues can be 
monomethylated or dimethylated symmetrically or asymmetrically(Bedford and 
Richard 2005).The methylation of lysines 4, 36, or 79 of histone H3 is typically 
associated with active transcription, while the methylation of lysines 9 or 27 on 
histone H3 and lysine 20 on histone H4 contributes to repressed transcription. 
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Figure 3. History, Mechanism, and Specificity of KMTs and KDMs (Black, Van Rechem et al. 2012) 
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I.B.4. Histone Lisine Methilation Family (KMT) 
KMTs catalyze mono-, di-, or tri-methylation by transferring one, two, or three methyl 
groups, respectively, from S-adenosyl-L-methionine to the 1-amino group of a lysine 
residue. Except for KMT4/DOT1L, all known KMTs contain a conserved SET 
(Su(var)3-9, Enhancer of Zeste, Trithorax) domain harboring the enzymatic activity. 
Besides the SET domain, most KMTs also contain some other defined protein 
domain or homologous sequence that is used to classify KMTs into distinct 
subfamilies. The enzymatic activities and substrate specificities of the eight KMT 
subfamilies are summarized here (Figure 4). Most KMT1 group proteins are 
members of the SUV39 family that specifically methylate H3K9. This family includes 
KMT1A/SUV39H1, KMT1B/SUV39H2, KMT1C/G9a, KMT1D/EHMT1/GLP, 
KMT1E/SETDB1, and KMT1F/SETDB2. They are the dominant enzymes generating 
H3K9 trimethylation (H3K9me3) at pericentric heterochromatin, a highly compacted, 
transcriptionally silent chromatin domainThe KMT2 family includes Drosophila 
Trithorax homologs MLL family proteins (MLL1–MLL5, named KMT2A–KMT2E, 
respectively). All KMT2 family proteins are H3K4 methyltransferases, and they share 
a distinct SET domain with an essential post-SET region at the C-terminus. 
KMT2A/MLL1 is a major regulator of hematopoiesis and embryonic development 
through regulation of HOX gene expression, and the MLL gene is frequently 
rearranged in human acute leukemias. The KMT3 family includes yeast Set2 
homolog SETD2/KMT3A, nuclear receptor binding SET domain protein 1, 
NSD1/KMT3B, and SET and MYND domain-containing proteins SMYD2/KMT3C, 
SMYD1/KMT3D, and SMYD3/KMT3E. This group of proteins methylates mainly 
histone H3K36, but their KMT activities are not restricted to H3K36. KMT3A is a 
Huntingtin interacting protein, and it is responsible for global transcription-dependent 
H3K36 trimethylation, a specific epigenetic mark for transcriptional activation 
enriched at the gene body. KMT3B is involved also shown to methylate H4K20. A 
recurrent translocation of KMT3B fused to nucleoporin-98 has been reported in 
childhood acute myeloid leukemia. KMT4/DOT1L is a H3K79-specific 
methyltransferase and represents the only class of KMT without a SET domain. 
KMT4-mediated H3K79 di- and tri-methylation are evolutionarily conserved from 
yeast to human and ubiquitously correlated with active transcription. It is the sole 
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enzyme responsible for H3K79 methylation.In mammals, KMT4 is an essential gene 
for embryogenesis, hematopoiesis, and cardiac function. Its H3K79 methylation 
activity is essential for MLL-AF4 and MLL-AF9 fusion-induced leukemias, suggesting 
that KMT4 could serve as a potential therapeutic target for MLL-rearranged 
leukemias. The KMT5 family consists of enzymes that methylate H4K20. 
KMT5A/SET8 specifically mono-methylates H4K20, which has been shown to 
associate with both gene repression and activation, depending on its chromatin 
context. KMT5A and H4K20me1 are also essential for multiple other chromatin-
associated processes, such as cell cycle progression, DNA replication, and DNA 
damage response. KMT5B/SUV420H1 and its homolog KMT5C/ SUV420H2 catalyze 
di- and tri-methylation of H4K20, which, along with H3K9me2/3, is essential for 
maintenance of repressive heterochromatin at pericentric and telomeric regions. 
KMT6A/EZH2, and KMT6B/ EZH1 belong to the KMT6 family. The methylation 
activity of KMT6A and KMT6B requires other core components of their associated 
protein complex, polycomb repressive complex 2 (PRC2). As the catalytic subunit of 
PRC2, KMT6A participates in maintaining the transcriptional repressive state of 
chromatin and is upregulated in a broad range of human cancers. This family 
contains only one protein, SET7/9, which monomethylates histone at H3K4. KMT7 
was found to methylate, besides histone, a number of non-histone proteins, including 
p53, DNA methyltransferase 1 (DNMT1), estrogen receptor alpha (ERa), nuclear 
factor kappaB (NFkB), and components of the TATA binding protein (TBP) complex, 
TBP-associated factors TAF10 and TAF7. The consensus recognition sequence in 
substrates for SET7-mediated lysine methylation, K/R–S/T–K ,is also recognized by 
the H3K4 demethylase KDM1A/LSD1, which is capable of removing the methyl mark 
on most of these substrates. Therefore KMT7/KDM1A has emerged as a classic 
model for dynamic lysine methylation of both histone and non-histone proteins. 
Currently this family comprises only one member, PRDM2/RIZ1. KMT8 was identified 
as retinoblastoma (RB) protein-interacting zinc-finger protein (RIZ1), and it belongs to 
the PRDM family of proteins which are characterized by the presence of a N-terminal 
positive regulatory (PR) domain (PRDI-BF1 and RIZ). The PR domain is a homolog 
of the SET domain and shares 20%–30% identity with the SET module. Some PR 
domains show intrinsic methyltransferase activity, whereas the methylation activity of 
most other PRDM proteins has not been identified. KMT8 possesses H3K9 
methylation activity and functions as corepressor for gene regulation. Many other 
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PRDM proteins, although lacking methylation activity, also play a role in regulating 
chromatin dynamics during stem cell self-renewal, differentiation, and 
development.(Zhang, Wen et al. 2012). 
 Figure4 Human KMTs and their histone and non-histone substrates (Zhang et al., 2012) 
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I.B.5. Histone Lisine Demethylation Family (KDMs) 
Histone lysine methylation was regarded as enzymatically irreversible for decades 
until the recent discovery of the first histone KDM, LSD1/KDM1A. Soon after, Jumonji 
(JmjC) domain was identified as another module that possesses enzymatic activity in 
removing methyl groups from lysine residues. As a large number of proteins in the 
human genome contain the JmjC domain, numerous JmjC domain-containing KDMs 
were discovered in the past few years, which in turn provide novel insights into the 
mechanisms of histone modification and epigenetic regulation. Like the KMTs, KDMs 
are classified according to the new nomenclature into several distinct groups based 
on their substrate specificities and protein domain organization (Figure 5). 
KDM1A/LSD1 is a flavin adenine dinucleotide-dependent monoamine oxidase that 
can remove mono- and di-methyl, but not tri-methyl, groups from methylated lysines 
such as H3K4. Other core components of its protein complex, such as CoREST and 
BHC80, are essential for its demethylating activity on nucleosomes. KDM1 has been 
shown to alter its substrates’ specificity toward H3K9 methylation when associated 
with nuclear receptors, there by acting as a transcriptional coactivator. Furthermore, 
KDM1 has a broad spectrum of non-histone substrates, such as p53 and DNMT1. As 
a homolog of KDM1A, KDM1B/LSD2 was recently identified and characterized as 
another H3K4 demethylase. In contrast to KDM1A, which functions at promoters, 
KDM1B removes intragenic H3K4 methylation for gene activation. Like KDM1A, 
KDM1B was reported to be able to remove mono- and di-methylation at histone 
H3K9. KDM2A and KDM2B demethylate mono- and di-methylation from H3K36, 
while KDM2B is also implicated in demethylation of H3K4. This family of proteins has 
been shown to function as transcriptional corepressors for regulation of several 
tumor-associated genes, including c-Jun and p15Ink4b. KDM3 family of proteins was 
identified as the second family of JmjC histone demethylases (JHDM2). 
KDM3A/JHDM2A and KDM3B/JHDM2B have specific action toward mono- and di-
methylation of H3K9, and they therefore function as transcriptional coactivators for 
gene expression. KDM3A and 3B have been shown to be involved in multiple 
biological processes such as androgen receptor (AR) signaling and 
spermatogenesis. Another JHDM2 family member, JHDM2C/ TRIP8, has not yet 
been shown to have enzymatic activity. The KDM4 family encompasses four 
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homologous demethylases, KDM4A–4D (JMJD2A–2D, respectively). KDM4 proteins 
are the first demethylases that show demethylation activity on trimethylation. All 
KDM4 family members are able to remove di- and tri-methylation from H3K9 and/or 
H3K36. Besides the JmjC domain, they share a highly conserved JmjN domain, and 
three of them (all except KDM4D) contain tandem PHD fingers and Tudor domains 
that read distinct histone methylation. KDM4 family proteins function in hormone 
response. KDM5 family members KDM5A–5D/JARID1A–1D specifically remove di- 
and tri-methylation from H3K4. They are multi domain-containing proteins 
characterized by a combination of JmjC and JmjN catalytic domains with an ARID 
DNA-binding domain, a C5HC2 zinc finger, and two to three PHD fingers. Distinct 
PHD fingers of KDM5A and KDM5C were shown to bind methylated H3K4 or H3K9, 
respectively.KDM6 This family comprises two H3K27-specific histone demethylases, 
KDM6A/UTX and KDM6B/JMJD3, which are capable of removing di- and tri-
methylation from H3K27. As H3K27 methylation is a repressive epigenetic mark 
elevated in multiple cancers, both KDM6A and KDM6B function as tumor 
suppressors, implicated in gene transcriptional activation, epigenetic reprogramming, 
and RB-dependent cell fate control. The KDM7/ PHF2 family consists of three 
members: KDM7A/JHDM1D, KDM7B/PHF8, and KDM7C/PHF2, which are involved 
in regulation of the expression of ribosomal RNA and genes involved in X-linked 
mental retardation. This family of proteins possesses strong demethylation activity 
toward H3K9 and H3K27 mono and di-methylation. Furthermore, PHF8 is able to 
remove mono-methylation from H4K20. All three KDM7 family proteins contain a 
PHD finger that binds to histone H3K4me3, and this recognition is essential for their 
substrate specificity, genomic occupancy, and regulation of target gene 
expression.(Zhang, Wen et al. 2012) 
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Figure5 Human KDMs and their substrates( Zhang et al., 2012) 
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I.B.6. Drugs Regulating Lysine Methylation 
The emerging fundamental roles have implicated that development of inhibitors for 
KMTs are a new frontier for drug discovery. However, so far, only a few compounds 
targeting KMTs are available for preclinical and clinical development due to their 
toxicity. Some of the first-generation inhibitors for KMTs are derived from natural 
products KMT enzymes catalyze the transfer of one to three methyl groups from 
Sadenosylmethionine (SAM) to specific lysine residues on histones. Targeting the 
cofactor (SAM) binding site of protein methyltransferases appears to be the first 
approach for KMT inhibition. Sinefungin A, is the first SAMcompetitive and 
nonselective inhibitor of KMTs identified. Another natural KMT inhibitor is the 
Chaetocin a fungal metabolite, it is inhibitor of the Drosophila melanogaster Suv39 
family including Suv39h1. A recent attempt at total synthesis of (+)-chaetocin 
enantiomers has showed that they also have inhibitory activity towards G9a. 
Chaetocin has also been reported to exhibit anti-myeloma activity, and can inhibit 
Suv39h1 in acute myeloid leukemia cells with hypermethylated tumor suppressor 
genes. These results support the potential of developing chaetocin H3K9 
methyltransferase inhibitors as therapeutics to target reactivation of silenced genes. 
Gliotoxin analogs with a disulfide bond, show potent inhibitory activity of G9a and 
Suv39h1without affecting SET7/9. In another high throughput screen against a 
preselected chemical library, a highly selective small inhibitor of G9a, BIX-01294 
(diazepinquinazolin-amine derivative) has been identified to lower bulk H3K9 me2 
levels in mouse ES cells and fibroblasts, with levels restored upon removal of the 
inhibitor. BIX-01294 binds at the protein substrate channel of G9A and GLP1. 
Recently, second-generation inhibitors, such as E72, UNC321, UNC0638, and 
UNC0646 that are based on a 7-alkoxyamine tethered to the quinazoline core, have 
been developed with a marked improvement of potency and specificity against 
G9a/GLP. Among them, UNC0646 has also demonstrated improved potency of this 
quinazoline series in cell based assays. In addition, reported that BRD4770, a 
compound from a focused library of 2-substituted benzimidazoles as a potential SAM 
mimetic, reduced cellular levels of di- and trimethylated H3K9, induced senescence 
and inhibition of cell growth in the pancreatic cancer cell line PANC-1The DOT1L 
inhibitor EPZ004777 is also a SAM analogue and binds to the SAM binding 
site.EPZ004777 has been shown to kill mixed lineage leukemia cells with little effect 
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on non-MLL-translocated cells. In addition, EPZ004777 increases the survival of 
mice bearing tumors with MLL translocation. EZH2 is essential for cancer stem cell 
self-renewal. A potent SAM hydrolase inhibitor, 3- Deazaneplanocin A (DZNep), has 
been shown to selectively inhibit EZH2, leading to H3K27 demethylation and 
induction of apoptosis in breast cancer cells but not in normal breast epithelial cells. 
SMYD2 exhibits oncogenic properties by repressing the functional activities of p53 
and retinoblastoma protein. Therefore, SMYD2 is an attractive drug target for the 
development of small-molecule inhibitors.(Tian et al. 2013) 
 
I.B.7. The Role of KMTs in Models of Neurological Disease 
 
I.B.7.1. Huntington’s Disease (HD )and Friedreich's Ataxia 
From a genome-wide perspective, other types of histone modifications show a 
distribution that is highly complementary to most (histone) acetylation marks. For 
example, the di- and tri-methylated forms of histone H3-lysine 9 are typically enriched 
in heterochromatin and, when present at the sites of promoters, these marks are 
typically involved in transcriptional repression and silencing. These mechanisms 
likely contribute to the neurobiology of disease. For example, dysregulation of H3-
methyl-lysine 9 was reported in postmortem brain studies of subjects diagnosed with 
Huntington’s disease or Friedreich’s Ataxia ,both of which are triplet repeat disorders. 
If the upregulation of histone acetylation generally seems to be beneficial for 
neuronal functions and behaviors, then what phenotype would be expected in 
genetically engineered animals with neuron-specific elevations of repressive 
chromatin marks such as H3-tri(di-)-methyl-lysine 9? This was examined using 
transgenic mice overexpressing the H3K9-specific histone methyltransferase, SET 
domain bifurcated 1 (Setdb1), also known as Erg-associated protein with SET 
domain. When expression in adult brain is upregulated (via transgenes expressed 
under control of neuron-specific promoters), levels of trimethylated H3 lysine 9 in 
heterochromatin surrounding pericentromeric repeat DNA became significantly 
elevated. Preliminary results from ongoing studies indicated that gross neurological 
function in these mice, as evaluated by rotarod and locomotor assays, body weight, 
and breeding behaviors were either normal or showed only subtle changes. 
However, preliminary findings suggest that Setdb1-overexpressing mice outperform 
their wild-type littermates in the Morris Water Maze and the Object Recognition tests, 
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which are thought to relate to hippocampus- and cortex-related memory functions . 
These findings were unexpected and suggest that therapeutic benefits in preclinical 
models of memory disorders are not limited to HDAC-mediated histone acetylation, 
but the mechanisms by which Setdb1- mediated H3-lysine 9 methylation alters 
neuronal function and behavior remain to be explored.(Jiang et al. 2008). 
 
I.B.7.2. Stroke In Vivo and Vitro 
Stroke, caused due to the interruption of cerebral blood supply, is a major cause of 
death after heart disease, and cancer. It has worldwide prevalence and is a highly 
debilitating disorder where most of the survivors suffer from permanent neurological 
disorders. Unfortunately, the treatment options for alleviating the stroke-associated 
conditions are limited both in terms of available drugs and the narrow time window for 
the therapeutic intervention. In rodents, various reliable models for inducing cerebral 
ischemia have been developed to study pathophysiology, cellular, and molecular 
processes involved in the cerebral infarction and also in evaluating the efficacy of 
potentially therapeutic molecules. During last few decades, most of the cellular and 
molecular investigations employed the middle cerebral artery occlusion (MCAO) 
model in rodent that represents stroke conditions in human. However, many clinical 
studies have shown that 13– 25% stroke cases are due to the internal carotid artery 
occlusion -a cerebral ischemic condition that may be asymptomatic to symptomatic. 
So, they established an Internal Carotid Artery Occlusion (ICAO) model in CD1 
mouse that resulted in mild to moderate level of neural damage mostly localized to 
the striatum. Recent molecular studies using various models of stroke in rodents 
have implicated epigenetic modifications that control transcription events such as 
DNA methylation and histone lysine acetylation and deacetylation, in ischemia-
induced damage and recovery. Administration of compounds that attenuate the 
methylation of DNA and increase the lysine (K) acetylation of histones H3 and H4 by 
blocking histone deacetylases (HDACs), have been shown to slow down ischemia-
induced neural damage. However, the role of other epigenetic mechanisms such as 
histone H3 and H4methylation and demethylation, in particular H3K9, H3K27 and 
H4K20 methylations, the transcriptionally repressive epigenetic modifications recently 
implicated in the etiopathology of most of the neurodegenerative and 
neuropsychiatric disorders, have little been investigated in ischemia or stroke 
models. Formisano et al. have recently shown that global ischemia induces 
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deacetylation of histones H3 and H4 and enhances H3K9me2 on MOR-1 (μ-opioid 
receptor) promoter in CA1 region of hippocampus causing a significant decrease in 
MOR-1 mRNA expression, leading to neurodegeneration. Another study by 
Schweizer et al., has also implicated H3K9 methylation and the role of histone lysine 
methyl transferases (KMTs) acting on this epigenetic modification, Suv39h1, and 
G9a, in hypoxia-induced oxidative stress and neuronal survival and death, using an 
in vitro OGD (oxygen glucose deprivation) model. The inhibition of transcriptionally 
repressive KMTs Suv39h1, and G9a using RNAi approach and specific inhibitor 
chaetocin, promoted neuronal survival partly mediated by enhancement of 
transcriptionally activating epigenetic mark H3K9ac (acetylation) on the promoter of 
brain-derived neurotrophic factor (BDNF) and its transcription in 
neurons.(Chakravarty et al. 2017)  
 
I.B.7.3. Wiedemann-Steiner Syndrome  
Mutations in KMT2A were reported to be associated withWiedemann-Steiner 
syndrome (WDSTS; OMIM 605130), an extremely rare neurodevelopmental condition 
accompanied by microcephaly, short stature, autism-like phenotype, and aggression. 
Interestingly, these abnormal brain functions were recapitulated in KMT2A 
heterozygous mutant mice, which displayed profound deficits in long-term contextual 
fear memory. In particular, neuronal ablation of KMT2A in the postnatal forebrain and 
adult prefrontal cortex exhibited increased anxiety and robust cognitive deficits in 
mice. In the same study, the analyzing H3K4me3 level and the gene expression 
profiles in KMT2A-deficient cortical neurons revealed that the homeodomain 
transcription factor, MEIS2, was repressed in these mice. Moreover, MEIS2 
knockdown in prefrontal cortex phenocopied memory defects elicited by the deletion 
of KMT2A, thus proposing a critical role of MEIS2 in the pathogenesis of 
WDSTS.(Kim et al. 2017) 
 
I.B.7.4. Kabuki Syndrome 1 
The most well-studied neurodevelopmental disorder associated with dysregulated 
H3K4me is Kabuki syndrome 1 (KABUK1; OMIM 147920), which is a rare congenital 
syndrome characterized by a distinctive face (a reminiscent of the make-up of actors 
Kabuki, traditional Japanese music-drama) and mental retardation with additional 
features including autism, seizure, and microcephaly. Heterozygous mutations in 
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KMT2D were found in more than 50% of patients with KABUK1, with the majority of 
mutations resulting in the premature termination of the protein product. In addition, 
mutations in KDM6A, an H3K27me demethylase gene, were also reported to 
contribute to less than 10% of this syndrome, and this type is referred as Kabuki 
syndrome 2 (KABUK2; OMIM 300867). Recently, Bögershausen et al. identified two 
mutations in RAP1A/B, which encode the Ras family small GTPases, in patients with 
KABUK1 by whole exome sequencing. The authors also demonstrated that mutant 
RAP1 morphant phenocopied KDM6A and KMT2D mutants in zebrafish, and that the 
MEK/ERK pathway signaling was perturbed in RAP1- and KMT2D-defective cells. 
Interestingly, these phenotypes were rescued by treatment with an MEK inhibitor. On 
the other hands, the reduction in neurogenesis and hippocampal memory defects 
exhibited in a KABUK1 mouse model were ameliorated by the treatment with a 
histone deacetylase (HDAC) inhibitor, AR-42. Furthermore, a ketogenic diet rescued 
hippocampal memory defects through the elevation of beta-hydroxybutyrate, an 
endogenous HDAC inhibitor, in the same mice model. Taken together, these results 
potentially provide diverse therapeutic directions to treat, or at least mitigate, the 
symptoms of KABUK1.(Kim, Lee et al. 2017) 
 
I.B.7.5. Schizophrenia 
Extensive exome sequencing from over 200 patients with schizophrenia (SCZD; 
OMIM 181500) revealed two de novo mutations in SETD1A, which likely cause 
malfunction of SETD1A activity. Furthermore, a strong association between the loss-
of-function mutation of SETD1A and SCZD was confirmed by analyzing the whole 
exome sequencing of over 4000 patients with SCZD. Interestingly, a recent 
bioinformatic analysis demonstrated that in addition to mutations in the protein coding 
region, mutations in the regulatory elements of SETD1A also contributed to the 
etiology of SCZD. De novo synonymous mutations within frontal cortex-derived 
DNase I-hypersensitive sites were enriched in SCZD, and SETD1A was identified as 
the highest statistical significant gene.(Kim, Lee et al. 2017) 
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I.C. SODIUM CALCIUM EXCHANGER 
I.C.1. State of Art of Na+/Ca2+ Exchanger (NCX) 
The Na+/Ca2+ exchanger (NCX) consists of 9 transmembrane segments that can 
mediate Ca2+ and Na+ fluxes across the plasma membrane(Blaustein and Lederer 
1999) (Figure 6). In particular it is distributed throughout the brain and the heart. 
These laboratories individually discovered the presence of a countertransport 
mechanism that exchanged Na+ and Ca2+ ions across the plasma membrane of 
different excitable but also non excitable cells. In 1988 and in 1990, Philipson and 
colleagues successfully performed the purification and cloning of the first isoform of 
NCX, the so-called NCX1, and some years later, the same investigation group cloned 
NCX2 (Li et al. 1994) and NCX3 (Nicoll et al. 1996). Among NCX isoforms, NCX2 
and NCX3 are selectively expressed in the brain (Lee et al. 1994) and in the skeletal 
muscle (Nicoll, Quednau et al. 1996) .The regulation of intracellular ionic 
concentrations of the previously mentioned cations, plays important roles in several 
cellular homeostasis mechanisms in excitable cells. In fact, sodium regulates cellular 
osmolarity, plays a crucial role in the induction of action potential (Lipton 1999), and 
also acts in transducing signaling pathways (Yu and Colvin 1997). Importantly, also 
calcium is involved in several cytosolic intracellular signaling mechanisms as second 
messenger. The sodium calcium exchanger works in association with other selective 
ionic channels and ATP-dependent pumps involved in the physiological mechanism 
of regulation of cytosolic ions concentrations (Blaustein and Lederer 1999). 
Depending on the intracellular concentrations of Ca2+ [Ca2+]i, and Na
+, [Na+]i, NCX 
can operate either in the forward mode, coupling the uphill extrusion of Ca2+ to the 
influx of Na+ ions, or in the reverse mode, mediating the extrusion of Na+ and the 
influx of the Ca2+ ions (Blaustein and Lederer 1999; Philipson and Nicoll 2000). The 
stechiometry of NCX is generally accepted to be three Na+ ions/one Ca2+ ion; 
however, at a later time, in addition to the major 3:1 transport mode, it has been 
demonstrate that ion flux ratio can vary from 1:1 to a maximum of 4:1, depending on 
[Na+]i and [Ca
2+]i (Fujioka et al. 2000; Kang and Hilgemann 2004).  
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Figure 6. Molecular topology of NCX (Annunziato et al., 2004). 
 
I.C.2. Molecular Biology of NCX 
The Na+/Ca2+ exchanger belongs to the superfamily of membrane proteins 
comprising the following members:  
1. the NCX family, which exchanges three Na+ ions for one Ca2+ ion or four Na+ 
ions for one Ca2+ ion depending on [Na+]i and [Ca
2+]i (Fujioka, Hiroe et al. 
2000; Kang and Hilgemann 2004) 
2. the Na+/Ca2+ exchanger K+-dependent family, which exchanges four Na+ ions 
for one Ca2+ plus one K+ ion (Lytton et al. 2002) 
3. the bacterial family which probably promotes Ca2+/H+ exchange(Cunningham 
and Fink 1996)  
4. the nonbacterial Ca2+/H+ exchange family, which is also the Ca2+ exchanger of 
yeast vacuoles(Pozos et al. 1996)  
5. the Mg2+/H+ exchanger, an electrogenic exchanger of protons with Mg2+ and 
Zn2+ ions (Shaul et al. 1999)  
These membrane proteins are all peculiarly characterized by the presence of α-
repeats, the regions involved in ion translocation. About the NCX family, three 
dominant genes coding for the three different NCX1, NCX2 and NCX3 proteins have 
been identified in mammals. These three genes appear to be dispersed, since NCX1, 
NCX2 and NCX3 have been mapped in mouse chromosomes 17, 7, and 12, 
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respectively (Nicoll, Quednau et al. 1996). At the post-transcriptional level, at least 17 
NCX1 and 4 NCX3 proteins are generated through an alternative splicing of the 
primary nuclear transcripts (Quednau et al. 1997). These variants arise from a region 
of the large intracellular f loop, are encoded by six small exons defined A to F, and 
are used in different combinations in a tissue-specific manner (Lee, Yu et al. 1994). 
To maintain an open reading frame, all splice variants must include either exon A or 
B, which are mutually exclusive. Excitable tissues, such as those of the brain and 
heart, are usually characterized by the presence of exon A, whereas kidney, 
stomach, and skeletal muscle tissues comprise NCX with exon B (Quednau, Nicoll et 
al. 1997). 
NCX1 is composed of 938 aminoacids, in the canine heart, having a theoretical 
molecular mass of 120 KDa and containing nine transmembrane segments (TMS). 
NCX1 amino-terminus is located in the extracellular space, whereas the carboxyl 
terminus is located intracellularly (Figure 6). The nine transmembrane segments can 
be divided into an N-terminal hydrophobic domain, composed of the first five TMS (1-
5), and into a C-terminal hydrophobic domain, composed of the last four TMS (6-9). 
These two hydrophobic domains are important for the binding and the transport of 
ions. The first (1-5) TMS are separated from the last four (6-9) TMS through a large 
hydrophilic intracellular loop of 550 amino acids, named the f loop (Nicoll et al. 1999). 
Although the f loop is not implicated in Na+ and Ca2+ translocation, it is responsible for 
the regulation of NCX activity elicited by several cytoplasmic messengers and 
transductional mechanisms, such as Ca2+ and Na+ ions, NO, phosphatidylinositol 4,5 
bisphosphate (PIP2), protein kinase C (PKC), protein kinase A (PKA), and ATP. In 
the center of the f loop, a region of approximately 130 amino acids in length has been 
reported to exert a Ca2+ regulatory function. This region is characterized by two Ca2+ 
binding domain (CBD1 and CBD2) that undergo conformational changes upon 
binding of Ca2+ and look very similar in the Ca2+ bound form, whereas in the absence 
of Ca2+, the domains show dramatic structural differences. CBD1 binds Ca2+ with Kd 
values of 120 and 240 nM, whereas the respective values of CBD2 are 820 nM and 
8,6 µM (Figure 7) (Hilge et al. 2006). At the N-terminal end of the f loop near the 
membrane lipid interface, an autoinhibitory domain, rich in both basic and 
hydrophobic residues, named exchange inhibitory peptide (XIP)(Matsuoka et al. 
1997), has been identified. The f loops also characterized by alternative splicing sites 
named β1-repeat and β2-repeat. These β-repeats are characterized by similar 
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regions comprising 60 to 70 amino acids for which no functional role has been 
proposed (Hilgemann 1990). 
     
 
 Figure 7. Ca
2+ 
binding in CBD1 and CBD2 domains. (Hilge et al., 2006). 
 
The NCX protein aminoacid sequence found between TMS2 and TMS3 is called α-1 
repeat, whereas the one found between TMS7 and TMS8 is named α-2 repeat. Both 
these regions are located on the opposite site of the membrane and include two 
segments composed of 12 and 9 highly conserved residues separated by a non 
conserved segment of 18 to 20 amino acids (Nicoll, Quednau et al. 1996; Nicoll et al. 
2002). Since the putative α-helices of the α-repeats are amphipathic, the hydrophilic 
faces of these helices may form a portion of the ion translocation pathway (Nicoll, 
Quednau et al. 1996).  
Interestingly, NCX2 and NCX3 have been found only in the brain and in the skeletal 
muscle. These two gene products consist of 921 and 927 amino acids and are 
characterized by molecular masses of 102 and 105 KDa, respectively. In addition, 
NCX2 displays a 65% sequence identity with NCX1, whereas NCX3 possesses a 
73% sequence identity with NCX1 and 75% sequence identity with NCX2 (Nicoll, 
Quednau et al. 1996). All three NCX gene products share the same membrane 
topology.  
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In the central nervous system (CNS), the Na+/Ca2+ exchanger plays a fundamental 
role in controlling the changes in the intracellular concentrations of Na+ and Ca2+ 
ions. These cations are known to regulate neurotransmitter release, cell migration 
and differentiation, gene expression, and neurodegenerative processes. The NCX 
protein aminoacid sequence found between TMS2 and TMS3 is called α-1 repeat, 
whereas the one found between TMS7 and TMS8 is named α-2 repeat. Both these 
regions are located on the opposite site of the membrane and include two segments 
composed of 12 and 9 highly conserved residues separated by a non conserved 
segment of 18 to 20 amino acids (Nicoll, Ottolia et al. 2002). Since the putative α-
helices of the α-repeats are amphipathic, the hydrophilic faces of these helices may 
form a portion of the ion translocation pathway (Nicoll, Quednau et al. 1996). 
Interestingly, NCX2 and NCX3 have been found only in the brain and in the skeletal 
muscle. These two gene products consist of 921 and 927 amino acids and are 
characterized by molecular masses of 102 and 105 KDa, respectively. In addition, 
NCX2 displays a 65% sequence identity with NCX1, whereas NCX3 possesses a 
73% sequence identity with NCX1 and 75% sequence identity with NCX2 (Nicoll, 
Quednau et al. 1996). All three NCX gene products share the same membrane 
topology. In the central nervous system (CNS), the Na+/Ca2+ exchanger plays a 
fundamental role in controlling the changes in the intracellular concentrations of Na+ 
and Ca2+ ions. These cations are known to regulate neurotransmitter release, cell 
migration and differentiation, gene expression, and neurodegenerative processes.  
 
I.C.3.Distribution of NCX in Different Tissues 
NCX1 is the most expressed protein of the SLC8 gene (solute carrier gene) family 
encoding for the Na+- Ca2+ exchangers. It was chiefly characterized and cloned as 
cardiac protein, then it has been disclosed in brain and kidney and minimally in other 
tissues (Quednau et al. 2004). NCX1 gene is alternatively spliced into two well-
known sites giving tissue specificity (Lipton 1999). The first site is located at the 5' 
untranslated region (5′ UTR) and does not alter the structure of the encoded protein. 
Otherwise, the presence of three different promoters independently drives the tissue 
specific expression for NCX, supposedly in response to different physiological 
requirements. (Nicholas et al. 1998).The second site of splicing takes place into the 
coding region of NCX transcript, whereas two mutually exclusive and four cassette 
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exons encode for a huge number of isoforms that differs just for the cytosolic inner 
portion of the exchanger (Lee, Yu et al. 1994). 
The two mutually exclusive exons includes the exon A in the transcript of excitable 
cells, primarily muscular and nervous cells, and the exon B in non-excitable cells. 
Nowadays, a combinatory pattern for cassette exons in tissues is not still available. 
Unlike NCX1, the other members of the SLC8 family show a more stringent tissue-
specific expression pattern. In fact, NCX2 is present in neurons, but minimally in 
other sites and NCX3 was found mainly expressed in the brain and skeletal 
muscle(Papa et al. 2003). Recently, NCX3 has been detected also in the immune 
system and bones. Remarkably, NCX3, but not NCX2, is alternatively spliced and 
these spicing variants differ for the cytoplasmic region as it has already been 
demonstrated for NCX1. Since the three Na+ - Ca2+ exchangers, NCX1, NCX2 and 
NCX3 isoforms display a high homology of sequence, it is widely accepted that 
structure and the functional role of NCX1 can be generally extended also to NCX2 
and NCX3 isoforms (Quednau, Nicoll et al. 2004). 
 
I.C.4. Regulation of Na+/Ca2+ Exchanger Isoforms 
Several factors are involved in the regulation of Na+/Ca2+ exchanger activity: the 
intracellular pH; metabolic related compounds, ATP, PA, PIP2, PKA, and PKC; redox 
agents, hydroxyl radicals, H2O2, dithiothreitol (DTT), O2
- ,Fe3+, Fe2+, Cu2+, OH, 
glutathione reduced (GSH), and glutathione oxidized (GSSG); and the gaseous 
mediator, NO. The site level at which [Ca2+]i regulates NCX activity is different from 
the one required for Ca2+ transport (Levitsky et al. 1994). The removal of intracellular 
Ca2+ ions completely blocks NCX activity (Philipson and Nicoll 2000). The location of 
such regulatory site has been identified in the 134-amino acid region, situated in the 
center of the f loop. In addition to intracellular Ca2+ regulatory site, an increase in 
[Na+]i can also regulate the Na
+/Ca2+ exchanger. In particular, when intracellular Na+ 
increases, it binds to the transport site of the exchanger molecule, and after an initial 
fast outward the Na+/Ca2+ current, an inactivation process occurs (Hilgemann et al. 
1992). This inactivation process, very similar to the phenomenon occurring in 
voltage-dependent ionic channels, is named Na+-dependent inactivation. The region 
of the intracellular f loop, in which this regulatory site is located, has been identified in 
a 20-aminoacid portion of the N-terminal part of the loop named XIP (Matsuoka, 
Nicoll et al. 1997). Regarding on the mechanism by which XIP inhibits NCX activity, it 
34 
 
has been proposed that when the XIP-binding site is ligand-occupied, a 
conformational change is induced in C-terminal portion of the f loop, thus resulting in 
the inhibition of the ion transport (Li et al. 1991). XIP is provided with relevant 
pharmacological implications. In fact, those exogenous peptides, having the same 
amino acid sequence as XIP, act as potent inhibitors of NCX activity (Annunziato et 
al. 2004b); (Pignataro et al. 2004b). Interestingly, Ca2+ ions, at low micromolar 
concentrations, binding its regulatory site, decrease the extent of this Na+-dependent 
inactivation. In fact, mutations in the Ca2+ regulatory binding site alter the activation 
and inactivation kinetics of exchange currents by modulating Na+-dependent 
inactivation (Matsuoka et al. 1995). H+ strongly inhibits NCX activity under steady-
state conditions (Doering and Lederer 1993). The action exerted by H+ ions is 
pathophysiologically relevant with regards to brain and heart ischemia. In fact, when 
intracellular H+ and Na+ ion homeostasis is deregulated, the anoxic conditions 
resulting in these cells may selectively interfere with the activity of the different NCX 
gene products. ATP may increase the activity of the exchanger in a number of ways. 
Firstly, ATP directly participates in the NCX molecule phosphorylation process by 
PKA and PKC (Caroni and Carafoli 1983). Secondly, it increases PIP2 production. 
This mechanism of activation is related to the relevant PIP2 influence on Na+-
dependent inactivation of NCX. In fact, PIP2 directly interacts with the XIP region of 
the exchanger, thus eliminating its inactivation and stimulating NCX function 
(Hilgemann and Ball 1996). Finally, by activating G-protein-coupled receptors, via 
endogenous and exogenous ligands, ATP can stimulate NCX activity through the 
pathway involving PKC or PKA activation (DiPolo and Beaugé 1998) .The 
mechanism underlying the phosphorylating effect on the exchanger seems to be 
related to an increase in its affinity for both internal Ca2+ and external Na+ and to a 
decrease in its inhibition by internal Na+. In addition, ATP cellular depletion inhibits 
NCX1 and NCX2, but does not affect NCX3 activity (Secondo et al. 2007). Moreover, 
phosphoarginine (PA) can stimulate NCX activity. In particular, PA present in 
millimolar concentrations in the cytosol, activates Na+/Ca2+ exchanger function in the 
forward mode of operation by intracellular Mg2+- and Ca2+-dependent way (DiPolo et 
al. 2004). Several groups of investigators also have found that NCX is sensitive to 
different combinations of redox agents (Amoroso et al. 2000); (Santacruz-Toloza et 
al. 2000). In particular, the stimulation of the exchanger activity requires the 
combination of a reducing agent with an oxidizing agent. The effects of both agents 
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are mediated by metal ions. The antiporter’s sensitivity to changes in the redox status 
can assume particular relevance during oxidative stress. In fact, in this condition, the 
modulation of reactive oxygen species (ROS) could affect the transport of Na+ and 
Ca2+ ions through the plasma membrane (Santacruz-Toloza, Ottolia et al. 2000). The 
ubiquitous gaseous mediator NO seems to be involved in the modulation of NCX 
activity. In fact, there are several evidences that NO, released by NO donors, is able 
to stimulate NCX in the reverse mode of operation in neuronal preparations and 
astrocytes. By contrast, in C6 glioma cells, the stimulatory action on NCX reverse 
mode of operation, elicited by the sodium nitroprusside (SNP), is not elicited by NO 
release but by the presence of iron in SNP molecule (Amoroso, Tortiglione et al. 
2000). In addition, the relationship between the constitutive form of nitric oxide 
synthase (NOS) and NCX has recently been demonstrated. Indeed, heat stress by 
inducing NOS phosphorylation causes NOS complexation with NCX, thus decreasing 
its activity (Kiang et al. 2003). 
 
I.D. NCX3 Na+/Ca2+ EXCHANGER 3 
The cloning of the Na+- Ca2+ exchanger isoform 3 (NCX3) was achieved from rat at 
the Philipson’s laboratory in 1996 (Nicoll, Quednau et al. 1996).NCX3 displays 
approximately the 80% sequence homology with the other isoforms of the Na+-Ca2+ 
exchanger family NCX, including NCX1 and NCX2. The NCX structure expresses a 
different percentage of homology within the isoforms sequence. For istance, the 9 
transmembrane domains share more than the 75% of homology within NCX1 and 
NCX2, but not the cytoplasmic f-loop with just the 60%, thus suggesting that the 
transport mechanism requires the conservation of the transmembrane regions, 
whereas the NCX3 capacity is specifically restricted to the cytoplasmic loop. The 
exact structure of calcium-binding domain (CBD1) of NCX3 remains unknown. 
Nonetheless, the conservation of some key acidic and basic residues leads to the 
same Ca2+ binding sites and a structure most likely similar to NCX1. Therefore, the 
regulation of NCX3 capacity of exchange by CBD1 is probably comparable to NCX1 
(Hilge et al. 2009).The comparison of CBD2 has proven to be more difficult because 
of the alternative splicing of the NCX family causing various possibilities of sequence 
for CBD2. The NCX gene is spliced in different variants. It has been described more 
than 15 splicing variants for the isoform 1 and a exiguous number of variants for 
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NCX3. NCX2 is the unique gene that does not present alternative splicing forms. 
NCX1 gene displays a tissue specific distribution.(Kofuji et al. 1994; Quednau, Nicoll 
et al. 1997; Dyck et al. 1999).The NCX3 gene is composed of 9 exons (exons from 1 
to 9) .(Quednau, Nicoll et al. 1997). Interestingly, exon 2 and 3– also named exon A 
and B, respectively - are mutually exclusive, whereas exon 4, named exon C, is 
optional. Thus, in the rat, three splice variants are detected. A variant containing 
exon A and C is found in skeletal muscle (NCX3-AC), while variants expressing the 
exon B are expressed in the brain (NCX3-B and NCX3-BC). Furthermore, in humans 
three truncated forms of NCX3 have been discovered of which two variants are 
expressed in the fetal brain (exons4- 9 and 6-9)(Lindgren et al. 2005).The third 
truncated variant is expressed in skeletal muscle (exons 2 and 6- 9) (Gabellini et al. 
2002).These human truncated forms are likely to be under the control of alternative 
promoters. Recently, the comparison of CBD2 deriving from NCX3-B and NCX1-AD 
exhibited a similar conformation in structures like the β-sandwich and the α-helix of 
the F-G loop (Breukels et al. 2012a). The splicing variants of NCX1 display a various 
orientation in the α-helix which has been found associated with the activation or 
inhibition during the rise in intracellular calcium [Ca2+](Giladi et al. 2015).Conversely, 
the NCX3 helix found subsequently to the splicing region shows a unique orientation 
among the splicing variants, expressing an [Ca2+]i-dependent activation. NCX1 exons 
A and B have been found not only individually involved in the signal transmission to 
the transmembrane domains, but also in the mechanism to relieve the Na+-mediated 
inactivation(Hilge, Aelen et al. 2009).The other NCX1 exons (C, D, E, and F) may 
regulate the Ca2+-binding affinity of CBD1. Overall, NCX3 splicing exons A, B and C 
are evolutionary well conserved among species, even a minor sequence homology 
compared with the NCX1 and NCX2 exons, which has been estimated 
approximatively around 55 and 65 %.Thus, it is quite impossible to apply the effect 
observed during the alternative splicing of NCX1 to NCX3. In addition, among the 
splicing variants, NCX3 exhibited different Ca2+ binding sites, which were identified 
three for NCX3-B and two for NCX3-AC. Interestingly, they expressed a different 
affinity for the Ca2+(Breukels et al. 2012b). According to the NCX structure, we can 
infer that differences among the axon A and B may have effect both on the Na+-
dependent inactivation (Hilge, Aelen et al. 2009) and on the sensitivity to Ca2+ 
through changes in conformation of CBD1-CBD2. Finally, we can assume that in the 
last years important works elegantly investigated the mechanism of translocation in 
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NCX and its regulation though CBD1 and CBD2 domains. Remains to reveal the 
mechanism that allows to the intracellular loop to influences the transmembrane 
segments and shed light on the role of the different alternatively splicing form of 
NCX3(Hilge, Aelen et al. 2009). 
 
I.D.1. Role and Mechanism of NCX3 in Brain Ischemic Preconditioning 
Recent findings demonstrated that the two isoforms of the Na+/Ca2+ exchanger,NCX1 
and NCX3, which are involved in several pathophysiological aspects of cerebral 
ischemia, can be included among the members of the growing family of the 
mediators involved in the ischemic brain tolerance due to their ability to regulate 
neuronal calcium homeostasis. In particular, we provide evidence that 
neuroprotection observed in preconditioned neurons exposed to OGD/reoxygenation 
is correlated to the increase in NCX1 and NCX3 protein expression. Indeed, the 
treatment with siRNA against NCX1and NCX3 prevents this effect. These data are in 
accordance with results recently observed in vivo in an animal model of IPC. 
Consistently with these results, the up regulation of NCX1 and NCX3 protein 
expression in neurons exposed to IPC was dependent on PI3K/Akt activation, since 
the treatment with LY294002 was able to abolish this increase. Interestingly, we 
demonstrated that NO plays a key role in the triggering PI3K/Akt pathway as the 
increase in the phosphorylated form of Akt observed within 30 min after IPC was 
completely abolished by the treatment with L-NAME. More importantly, the treatment 
with L NAME was able to inhibit NCX3 but did not affect NCX1 protein expression. It 
has recently demonstrated that in neurons NCX3, apart its localization on the plasma 
membrane, is also expressed on the outer mitochondrial membrane where it 
contributes to the extrusion of calcium from mitochondria. It is well known that 
mitochondria, in addition to the generation of cellular energy, play an important role in 
regulating cellular calcium homeostasis in concert with the sarco-endoplasmic 
reticulum Ca2+-ATPase(SERCA),the plasma membrane Ca2+-ATPase, and Na+/Ca2+ 
exchanger. On the other hand, the maintenance of mitochondrial calcium 
homeostasis is an important requirement ensuring mitochondrial function. Infact, 
Ca2+-sensitive dehydrogenases can regulate oxidative phosphorylation and ATP 
synthes is during times of high cellular demand. Therefore, it is possible to 
hypothesize that the increase dexpression of NCX3,we observed within 48 h from the 
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sub-lethal insult, might exert neuroprotective effects regulating calcium handling and 
improving mitochondrial oxidative capacity. This finding is in line with the results 
previously obtained in an in vitro model of IPC and demonstrating that the increase in 
nNOS expression and NO production through the activation of Ras/ERK1/2 pathway 
stimulated mitochondrial MnSOD. These effects associate with a reduction in free 
radical production and cytocrome c release from mitochondria to cytosol, and in turn 
with an improvement of neuronal survival. The demonstration that NCX3 might 
represent a target of IPC-induced neuroprotection adds new insight into the 
molecular mechanisms involved in the ischemic brain preconditioning. Indeed, the 
over-expression of NCX3 might help mitochondria to preserve their energetic 
capacity making them less vulnerable to the subsequent lethal insult represented by 
OGD/reoxygenation. This hypothesis was strongly supported by the results obtained 
measuring the activity of NCX during IPC. In fact, we demonstrated that IPC induced 
an increase of NCX activity in the reverse mode of operation that was still observed 
in preconditioned neurons exposed to OGD/Reoxygenation. This is an early event 
since it occurred within 30 min after IPC stimulus was due to the contribution of 
NCX1and NCX3 isoforms and was promoted by NO because it was abolished by the 
treatment with L-NAME. Intriguingly, this effect was associated with an increase in 
ER calcium content. Consistently with data previously published in our Laboratory, 
we speculated that NCX1, working in the reverse mode of operation, plays a key role 
in the regulation of ER calcium refilling in the early phase of IPC. Indeed, the 
treatment with siNCX1,but not siNCX3, was able to prevent this phenomenon. The 
novel aspect of the study is the demonstration that NO promoted NCX1-induced ER 
refilling that was hampered by L-NAME pretreatment. This finding is in accordance 
with data recently published by Secondo et al. and demonstrating that NO was able 
to stimulate NCX1 to work in the reverse mode of operation, whereas NO did not 
affect NCX3 activity. The possibility that NCX1 activation in the early phase of IPC 
could affect mitochondrial calcium content promoting mitochondrial calcium up take 
could not be excluded. However, in the late phase of IPC mitochondrial calcium 
handling is mainly regulated by NCX3 that is able to promote mitochondrial calcium 
extrusion. These data are supported by the finding that NCX3 expression increased 
48h after the IPC insult. We have previously demonstrated that NCX3 is distributed 
also at mitochondrial level; therefore, it is possible to speculate that during IPC, the 
increased expression of NCX3 on mitochondria might contribute to the efflux of 
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calcium from the organelle thus protecting neurons by the subsequent mitochondrial 
calcium overload induced by lethal OGD/reoxygenatione exposure. The finding that 
the treatment with CGP and siNCX3 counteracted the effect of IPC on mitochondrial 
calcium content, leading to the lack of IPC-neuroprotection, further supports this 
hypothesis. Collectively, we can conclude that a functional interplay between NCX1 
and NCX3 occurs during IPC. This phenomenon is tightly dependent on NO and Akt 
activation, and by contributing to the modulation of intracellular ionic homeostasis, 
could represent one of the mechanisms responsible for neuroprotection induced by 
IPC(Sisalli et al. 2015). 
 
I.D.2. Transcriptional Regulation of ncx3 Gene in Brain 
The human SLC8A3 minimal promoter was identified in the 250 bp region 
immediately upstream of the exon 1 . It shows features similar to the SLC8A1 brain 
promoter in that it includes SP1 and AP2 elements that confer constitutive 
transcription and tissue specific expression, respectively. The sequence of human 
SLC8A3 promoter and of the exon 1, as that of the rat brain SLC8A1 promoter, is 
very rich in GC bases. These form a typical cytosine and guanine dinucleotide (CpG) 
island as it occurs at the 5′ end of several housekeeping genes and oncogenes. 
While these GC rich sequences usually stay unmethylated, abnormal methylation 
occurs in some pathological conditions as during oncogenic transformation, e.g., the 
α2 (VI) collagene gene undergoes extensive methylation in SV-40 transformed 
fibroblasts that inhibit transcription from the AP2 sites. The sequence of the SLC8A3 
promoter and that of SLC8A1 brain promoter include multiple AP2 sites 
(GCCNNNGGC) potentially important for regulation in neurons. Members of the AP2 
transcription factor family have been shown to be important regulatory molecules for 
the vertebrate development of neuronal tube, neuronal crest derivatives, skin, and 
urogenital tissue. These members also show differences in spatial and temporal 
expression during mouse development . The tissue specific expression of AP2 is 
highest in ectodermal cell lineage, including neuroepithelium and neural crest. 
Several repeated consensus elements for transcription factors AP2 are found in 
neuron specific gene promoters (e.g., choline acetyltransferase, proenkephalin; 
human fragile mental retardation promoter [FMR1]) as well as in other cellular genes, 
(i.e.keratin, sodium-phosphate cotransporter [Npt2] of kidney proximal tubules and 
viral genomes as MMTV). In contrast to the SLC8A1 gene, whose transcription 
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initiates from multiple tissue-specific promoters, a single promoter region may 
determine the tissue-specific expression of the SLC8A3 gene. The SLC8A3 promoter 
indicates neuronal expression. Furthermore, it also includes elements for the muscle-
specific transcription factors MyoD and GATA factors 2/3; in agreement is the fact 
that the orthologrodent gene is predominantly expressed in brain and skeletal 
muscles. The SLC8A3 promoter also includes elements potentially binding inducible 
transcription factors AP1, and Egr-1 (also known as NGF1-A, Krox24, Zif/268, or Tis 
8). These are a subgroup of IEGs that are activated rapidly and transiently in 
neuronal cells in response to environmental stimuli, such as neurotransmitters and 
neurotrophin receptor stimulation. They regulate the expression of subsets of genes 
termed delayed-response genes. The AP1 complex is formed by the dimerization of 
the Jun proteins (c-Jun; JunB and Jun D) and Fos proteins (c-Fos, FosB, Fra-1, etc.) 
through their leucine zipper motifs. The AP1 complex binds to the consensus 
sequence TGACTCA. This element, also termed TPA response element (TRE), was 
first indicated as the element responsive to phorbol ester activation of protein kinase 
C (PKC). The Jun proteins can also form homodimers or heterodimers with Fos; 
dimerization with transcription factors of the ATF/CREB family is also possible. The 
composition of the AP1 complex can affect the affinity for consensus sequences and 
influence transactivation potential. The regulation of Jun and Fos proteins by 
phosphorylation has been deeply investigated and a considerable amount of 
literature is available. The transcription factors of the Egr or Krox family are rapidly 
induced in mammalian brain by a variety of stimuli; in contrast to Fos and Jun they 
lack the bZip domain and bind DNA by zinc finger motifs. The activation of the N-
Methyl D-Aspartate (NMDA) receptor by glutamate transiently induces Egr-1 within 
minutes, similarly to the induction of c-fos . The induction of Egr-1-mRNA has been 
reported in a variety of primary cultures of cerebellar, corticostriatal, cortical, and 
hippocampal neurons. The in vivo expression of Egr-1 is strongest in the 
hippocampus and cerebellum of adult rats and considerably high in neocortex, 
striatum, and hippocampal CA1 neurons. Following stimulation by intraperitoneal 
administration of NMDA, the Egr-1 mRNA increases in the cortex, cerebellum, and 
hippocampus. The blockade of NMDA receptor by MK-801 selectively downregulates 
the expression of Egr-1 but does not alter c-fos and AP1 expression . It has been 
suggested that the activation of NMDA receptor by physiological synaptic activity 
specifically increases the expression of Egr-1, whereas kainateevoked seizures 
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induced all four members of the Egr family. Thus, although the role of Egr-1 element 
in the regulation of SLC8A3 gene expression has not yet been documented 
experimentally, it seems likely that NMDA receptor activation may cause the 
upregulation of SLC8A3 mRNA. The consequent increase in NCX3 protein activity 
may be specifically required to extrude Ca2+ following its entry through the activated 
NMDA-receptor channel. A functional link between NMDA receptor and NCX3 is also 
suggested by their high expression in the hippocampus, especially in the CA1 region 
. The SLC8A3 promoter also indicates a CRE element–218 (TGACGTGC) originally 
identified in the promoter of the somatostatin gene as the 8-bp sequence 
TGACGTCA. The CRE element is included in several other cAMP-responsive gene 
promoters, such as cfos, Zif/268, or Egr-1 and proenkefalin. In addition, it was shown 
that the CRE element mediated the transactivation of the c-fos gene in response to 
Ca2+ influx as well as cAMP thus also named Ca2+ response element (CaRE). The 
presence of the CRE element has attracted much attention since it could confer rapid 
inducibility to the SLC8A3 gene, similar to that of IEGs. The SLC8A3 gene also 
includes several DRE elements (with central core nucleotide sequence GTCA) in the 
region downstream of the TATA box and in the exon 1, potentially able to bind the 
cAMP and Ca2+-regulated transcriptional repressor DREAM. The transcriptional 
regulation in response to BDNF, cAMP, and Ca2+ signals via the CRE and DRE sites 
will be examined in the following subheading.(Gabellini 2004). 
 
 
I.D.2.1 ncx3 Brain Promoter Region and Putative Transcription Factor in 
Binding Site 
The human genomic DNA region including the complete SLC8A3 gene was identified 
by similarity search (BLAST Human Genome) with the corresponding rat cDNA 
sequence and with a partial genomic sequence, which had been previously assigned 
to human isoform 2. The alignment of the predicted coding sequence with that of 
Rattus norvegicus Slc8a1 (AF109163), Slc8a2 (NM_078619) and Slc8a3 (U53420) 
clearly indicated high homology to rat isoform 3. The human SCL8A3 gene was 
identified within the genomic region 14q24.2 (sequence fragments AL160191.3 and 
AL135747.4, contig NT_010028.7, chr14:68875999–69023425). It includes nine 
exons, numbered 1–9. It should be noticed that exons 2–5 correspond to 
homologous exons 2–5 of the SLC8A1 gene; whereas the SLC8A3 gene exons 6–9 
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correspond to homologous NCX1 exons 9–12. Thus, SLC8A3 gene lacks the 
alternatively spliced exons 6–8. The sequence and the boundaries of exons 2–10 
(now 2– 7) were already known and the mutual exclusiveness of exons 3 and 4 was 
previously demonstrated (also termed A and B, Kofuji et al., 1994). The sequence of 
the remainder exons (1, 8 and 9) was predicted by the alignment of cDNA sequences 
with the highly similar rat isoform 3 and by the consensus for splice sites. The 
predicted human NCX3 protein is encoded by eight exons (2–9). The coding 
sequence specifies 928 or 927 amino acids, depending on the inclusion of exons 3 or 
4. The human SLC8A3 coding sequence exhibits 93% nucleotide conservation, and 
97% amino acid identity with the orthologous rat sequence. Successful amplification 
of the exon 1 was performed with the cDNA from SH-SY5Y cells, a neuroblastoma 
cell line that expresses high levels of NCX3 protein and was used for the analysis of 
the SLC8A3 proximal promoter region. The segment (752 bp) was amplified starting 
from nucleotide 6 of the exon 1 and 66 nucleotides downstream of the 50 of the exon 
2. Since exon 1, and the promoter region are located in a GC rich region, the yield of 
the amplification was low. Probably, the amplification of this segment from total 
human brain and human skeletal muscle cDNAs failed because the amount of 
SLC8A3 cDNA in tissues is lower than in the neuroblastoma cell lines. The 50 exon 1 
sequence of the SLC8A3 gene is more extended than that reported previously from 
the rat cDNA. Only the 30 portion of exon 1 (228 bp) displays a significant similarity 
to the corresponding region of the rat sequence. The whole SLC8A3 coding 
sequence was amplified by RT-PCR from the RNA of the human neuroblastoma 
SHSY5Y cell line. The amplified segment (2766 bp) was cloned in the pCR vector 
and further analyzed by DNA sequencing. The coding sequence matched perfectly 
that predicted by the computational analysis, except the small exon 5 was absent. It 
consists of six exons: 2, 4, 6, 7, 8, 9 . As in the case of the SLC8A1, the ATG start 
codon is close (63 bp) to the 50 end of exon 2. This exon encodes the largest portion 
of the NCX3 protein, whereas the remainder coding exons (3–8) are much smaller. 
The coding sequence terminates with a stop codon located at base 375 of exon 9. 
The sequence continues with a long 30 UTR (1733 bp) as established by the 
alignment of genomic DNA and human EST sequences: N50099 (99.7% identity) 
AW022249 (98.7%); AW903279 (100%), and cDNAs AF086064 (99.7%) and 
AL359938 (99.8%). The polyadenylation signal (AATAAA) was found by NIX polyA 
program 23 nucleotides upstream of the putative polyA site. The alignment of the 
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deduced amino acids sequence of human NCX3 with that of human NCX1 and NCX2 
showed 68% and 71% identities respectively, whereas that of NCX2 and NCX1 
showed 65% identities. The amino acid sequence of the human NCX3 protein was 
analyzed by Simple Modular Architecture Research Tools (SMART) computer 
programs. The Signal program predicted an N-terminal signal peptide (residues 1–
31), similar to that of NCX1. The TMHMM2 program predicted ten trans-membrane 
(TM) domains. The five N-terminal TM domains are clustered (amino acids 74–95, 
133–155, 170–189, 202–224, 229– 251). The large hydrophilic loop is located from 
positions 252–744. Five potential TM domains are predicted at the C-terminus of the 
protein (745–767, 782–801, 821–843, 853–875 and 896–918). The alternative 
splicing in the SCL8A3 region encoding the C-terminal portion of the large 
intracellular loop was analyzed by RT-PCR on the cDNA from SH-SY5Y cells, human 
skeletal muscle and whole brain. The amplification of the cDNAs from human brain 
and neuroblastoma cells produced only one band of 267 bp (Fig. 3, lanes A and C). 
The DNA sequence of several clones of the fragment was identical: all of them 
included exon 4. Thus, the NCX3 isoform expressed in brain has the same 
composition of the NCX3 isoform expressed in the human neuroblastoma cell line 
(AF510501), corresponding to the murine isoform named NCX3.2. The alternative 
splicing pattern of the NCX3 cDNA from human skeletal muscle is more complex. 
Three DNA fragments were amplified from this tissue: the most abundant DNA band 
corresponded to the NCX3.2 isoform including exon 4 (267 bp), whereas the largest 
fragment (285 bp) corresponded to the NCX3.3 isoform including the exon 4 and the 
small exon 5 (AF510502). The sequence of the smallest DNA fragment (164 bp) 
revealed a NCX3 isoform lacking both exons 3 and 4. We propose to name this 
newly identified isoform NCX3.4 (AF510503). The skipping of both exons 3 and 4 
caused a frame shift downstream of the exon 2. The NCX3.4 sequence encodes 620 
amino acids, of which 595 are encoded by exons 2 and 25 by the different frame in 
the exon 6. The NCX3.4 isoform has a predicted molecular weight of about 68 kDa; 
its domain composition is similar to a truncated NCX1 isoform previously described. 
No NCX3 isoform containing exon 3 was found in the human cDNA analyzed. The 
sequence analysis performed by SMART similarity search with PFAM (protein 
families database) domains indicated that the sequence encoded by exons 3 and 4 
(amino acids 595–630) overlaps the region encoding the second Calx-b domain 
(amino acids 519–619). Only 8 of the 25 amino acids specified by the different frame 
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of the exon 6 reconstruct a portion of the second Calx-b domain, the remaining C-
terminal sequence of isoform 3.4 includes several positively charged 
residues.(Gabellini, Bortoluzzi et al. 2002) 
 
I.D.2.2 ncx3 is Transcriptionally Up-Regulated by CREB 
In neurons, a wide range of extracellular stimuli activates signaling pathways like so 
CREB family members. Gene expression dependent by CREB pathway activation 
has been implicated in a complex and various series of processes ranging from 
development to plasticity, and eventually related also to diseases. CREB (cAMP 
response element binding protein) belongs to the bZIP superfamily of transcription 
factors. Within this superfamily, CREB and the closely related factors CREM (cAMP 
response element modulator) and ATF-1 (activating transcription factor 1) include a 
subcategory referred to as the CREB family. Belonging to the bZIP transcription 
factors, CREB family members contain a leucine zipper domain that facilitates CREB 
dimerization, and a C-terminal basic domain which role is binding with DNA. There is 
a high degree of homology among CREB, CREM, and ATF-1, allowing them to form 
both homo- and heterodimers, and each of these complexes takes place at the same 
side of cis-regulatory element as reviewed in (De Cesare et al. 1999; Shaywitz and 
Greenberg 1999). The remaining domains of CREB family members mediate the 
interaction with coactivators and components of the transcriptional machinery to the 
DNA, facilitating RNA synthesis of genes having an important role in the nervous 
system. The most common CREB isoforms, CREBα and CREBΔ, display a kinase 
inducible domain (KID) between two domains enriched of glutamine residues, the so-
called Q1 and Q2/CAD (constitutive active domain). The unique difference between 
these two activators is the presence of an α domain. Following stimulation, the KID 
domain phosphorylated at the residue of Serine 133 (Ser-133), can bind the 
transcriptional coactivator, CREB binding protein (CBP) via its KIX domain (Chrivia et 
al. 1993; Kwok et al. 1994). As result of the interaction stimulus-dependent between 
these two domains, the transcriptional machinery starts the synthesis of the inducible 
genes. Q2/CAD domain interacts with components of the basal transcriptional 
machinery allowing the stimulus-independent CRE-driven gene expression (Ferreri et 
al. 1994). The SLC8A3 promoter also indicates a CRE element–218 (TGACGTGC) 
originally identified in the promoter of the somatostatin gene as the 8-bp sequence 
TGACGTCA. The CRE element is included in several other cAMP-responsive gene 
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promoters, such as cfos, Zif/268, or Egr-1 and proenkefalin. In addition, it was shown 
that the CRE element 
mediated the transactivation of the c-fos gene in response to Ca2+ influx as well as 
cAMP thus also named Ca2+ response element (CaRE). The presence of the CRE 
element has attracted much attention since it could confer rapid inducibility to the 
SLC8A3 gene, similar to that of IEGs. (Gabellini 2004) 
 
 
I.D.2.3 ncx3 is Transcriptionally Down-Regulated by DREAM 
DREAM was primarily identified as the transcriptional repressor of the human gene 
for the opioid peptide dynorphin. Dynorphins are members of the opioid peptide 
family which are involved in memory formation and chronic pain adaptation. 
Dynorphin peptide controls the release of neurotransmitters as well as it can block 
LTP in the hippocampus by inhibiting excitatory neurotransmission from synaptic 
terminals.(Wagner et al. 1993; Weisskopf et al. 1993) The DNA sequence required 
for the transactivation of prodynorphin transcription via cAMP and Ca2+ has been 
identified in the first exon of the gene (at position +40), and termed dynorphin 
downstream regulatory element (DRE)(Carrion et al. 1998).The transcription factor 
binding to the DRE was subsequently identified and includes four Ca2+ binding 
domains of the EF hand type. Nowadays, it represents the unique transcription factor 
known to be directly regulated by Ca2+. When loaded with Ca2+, DREAM undergoes 
conformational changes causing its detachment from DRE sites, thus relieving the 
transcriptional repression(Herdegen and Leah 1998; Osawa et al. 2001).The ability to 
bind DNA of some members of the basic helix-loop-helix (bHLH) transcription factor 
family is also regulated by Ca2+, through the interaction with Ca2+-loaded calmodulin 
(Corneliussen et al. 1994; Onions et al. 1997). The DREAM sequence presumably 
includes four EF-hands, displaying high homology to Ca2+-binding proteins of the 
recoverin subfamily. Mutation of two residues within any of the functional EF-hands, 
the so-called EFmutDREAMs, did not affect the binding to the DRE but completely 
prevented the unbinding in the presence of increasing concentrations of Ca2+. It 
seems like the derepression of DRE-dependent gene expression after PKA activation 
(Carrion, Mellstrom et al. 1998)is related to specific protein–protein interactions 
between DREAM and nuclear effectors of the transcriptional effects of cAMP. 
Analysis of the 5’ regulatory regions of many Ca2+-regulated genes has shown the 
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presence of one or several functional DRE sites downstream from their TATA 
boxes(Carrion, Mellstrom et al. 1998; Ledo et al. 2000).This suggests that DREAM 
mediated transcriptional derepression is a generally required step prior to 
transcriptional activation of many genes. A new search showed identity between 
DREAM and calsenilin, a protein able to interact with presenilin-2 found in a yeast 
two-hybrid screen using the carboxy terminal part of presenilin-2 as a bait(Buxbaum 
et al. 1998). Double immunostaining after overexpression of N-tagged calsenilin in 
Cos cells showed the colocalization with presenilin-2 in the cytoplasm and the 
endoplasmic reticulum and suggested that the colocalization at the ER, in particular, 
was increased after calcium stimulation (Buxbaum, Choi et al. 1998).More recently, 
also using a yeast two-hybrid screen to identify components of the protein complex 
responsible for the A-type potassium currents, a protein identical to DREAM called 
KchIP-3 (potassium channel interacting protein 3) was found to selectively interact 
with the amino terminal region of Kv4 potassium channels (An et al. 
2000).Interestingly, the interaction with the potassium channel does not depend on 
the presence of calcium. However, the change in KchIP-3/DREAM conformation that 
follows binding to Ca2+ profoundly affects channel properties (An, Bowlby et al. 
2000). Interestingly, in this study two other proteins related to DREAM, KchIP-1 and -
2, were identified. In terms of the interaction with potassium channels, KchIP-1 and -
2 are similar to KchIP-3. However, it is not known whether they are also able to 
interact with presenilin-2 and especially, whether they are able to specifically bind to 
DNA. Thus, the possible existence of a DREAM family of nuclear repressors remains 
to be investigated. Taken together these results indicate that DREAM/KchIP-
3/calsenilin might have pleiotropic functions through the interaction with specific DNA 
sequences and/or with proteins in different cell compartments (Agell et al. 
1998).DREAM, calsenilin, and KChIP3 are the products of a unique gene(Buxbaum 
et al. 2000; Spreafico et al. 2001), although the proteins are localized in different 
cellular compartments: nucleus, endoplasmic reticulum, or lysosomes and plasma 
membrane, respectively. Regulation of mRNA translation at alternative start codons 
may generate proteins with variable N-terminal peptides, which could be important 
for their localization and function. Furthermore, isoforms lacking the EF-hand 
domains are generated by alternative splicing in mouse (Spreafico et al., 
2001(Gabellini 2004). The SLC8A3 gene also includes several DRE elements (with 
central core nucleotide sequence GTCA) in the region downstream of the TATA box 
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and in the exon 1, potentially able to bind the cAMP and Ca2+-regulated 
transcriptional repressor DREAM(Gabellini 2004). 
 
 
I.E. GATA TRANSCRIPTION FACTORS  
I.E.1. The GATA Transcription Factor Family 
The GATA-binding proteins are a group of structurally related transcription factors 
that bind to the DNA consensus sequence GATA. Members of the GATA protein 
family (GATA1-6) function as lineage-specific transcription factors for a number of 
cell types in the hematopoietic system (Chen et al. 2012). In vertebrates, six GATA 
transcription factors have been identified. Based on phylogenetic analysis and tissue 
expression profiles, the GATA family can be divided into two subfamilies, GATA1/2/3 
and GATA4/5/6 . Although in non-vertebrates GATA genes are linked together onto 
chromosomes, in humans they are segregated onto six distinct chromosomal 
regions, indicating segregation during evolution. Most GATA genes encode for 
several transcripts and protein isoforms. GATA proteins have two zinc finger DNA 
binding domains, Cys-X2-C-X17-Cys-X2-Cys (ZNI and ZNII), which recognise the 
sequences (A/T)GATA(A/G) (Figure 8). In non-vertebrates GATA transcription 
factors have been identified that contain mostly one zinc finger, i.e. in Drosophila 
melanogaster and Caenorhabditis elegans. The C terminal zinc finger (ZNII) exists in 
both vertebrates and non-vertebrates indicating that ZNI was duplicated from ZNII 
(Lentjes et al. 2016) 
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Figure8 Overview of GATA1-6 proteins (Lentjes et al., 2016)  
 
I.E.2. Structural Characteristics and Binding Site Specificity of the GATA 
Factors 
The function of GATA proteins depends critically on two highly conserved zinc fingers 
and nearby basic regions. The C-terminal ‘‘C-finger’’ and its adjacent basic region are 
necessary and sufficient for GATA to bind its cognate sequence, WGATAR (W = A/T, 
R = A/G). The N-terminal ‘‘N-finger’’ can also bind DNA independently but has a 
preference for GATC core motifs. Both fingers participate in binding the palindromic 
GATA motif ATCWGATA (W = A/T), resulting in markedly increased affinity. Recent 
chromatin immunoprecipitation sequencing (ChIP-seq) experiments on GATA1, 
GATA2, and GATA3 showed that GATA proteins mostly bind to a single GATA site 
((A/T)GATAA) or a palindromic site (catctGATAAG;). It is known that GATA can bind 
palindromic sites with high affinity and that such binding may be functionally 
important. However, it was not known until recently how prevalent this DNA-binding 
mode of GATA is in vivo. Compared with classical Cys2His2 zinc finger proteins, 
such as Zif268 and TFIIIA, the GATA proteins have a longer linker region, which 
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allows more complex and versatile DNA-binding patterns. Zif268 and TFIIIA have 
shorter linkers and use multiple zinc finger domains to wrap around DNA and track 
along the major groove. Our structure is also different from most other Cys4 zinc 
finger proteins, such as nuclear receptor proteins. Although most nuclear receptor 
proteins also have two Cys4 zinc finger motifs, they use one for DNA binding and the 
other for dimerization. In addition, nuclear receptors form dimers to bind the same 
side of the DNA, the N-finger binds to one side of DNA in the major groove and then 
tracks along the minor groove without DNA binding. The C-finger binds to the major 
groove on the other side of the double helix and then tracks along the minor groove 
with extensive DNA binding. Finally, the end of the C-tail reaches the N-finger and 
completes the wrapping architecture. Several structural features may account for the 
enhanced binding affinity of GATA to the palindromic sites. First the N-finger and C-
finger bind to adjacent sites on the DNA, making extensive protein-DNA contacts. 
Second, the binding of a zinc finger induces conformational changes of the DNA, and 
such changes may facilitate the binding of the second zinc finger to the adjacent site. 
Third, the N-finger and C-finger interact directly on palindromic sites, and these 
protein–protein interactions may lead to cooperative binding of the two fingers to 
DNA, similar to the cooperative binding of GATA C-fingers to adjacent sites. Finally, 
the N- and C-fingers, in conjunction with their C-terminal extensions, wrap around 
DNA in the palindromic complex, and such encirclement of DNA by the protein 
usually leads to enhanced kinetic stability of the protein/DNA complex. Given that it is 
well known that GATA proteins mediate long-range gene regulation, we believe that 
our model represents at least one of the mechanisms by which GATA proteins loop 
DNA in cells. In addition to direct DNA bridging, GATA proteins may loop DNA 
through indirect mechanisms, such as via their cofactors (e.g., FOG proteins), which 
have also been shown to play important roles in mediating DNA loop formation. 
Notably, these transcription factors are all implicated in lineage control during cellular 
differentiation. We thus propose that one mechanism whereby the epigenetic 
expression patterns of a given cell are controlled is specific folding of the three-
dimensional structure of the genome by transcription factors that control a given 
lineage. There are two distinct DNA-binding modes of GATA transcription factors: (1) 
the wrapping mode, in which both zinc fingers synergistically enhance the binding 
affinity and kinetic stability; and (2) the bridging mode, in which a single GATA DBD 
bridges two pieces of DNA. Because the DBDs of GATA proteins are highly 
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conserved, the structural features described here will likely hold true for all six GATA 
family members. The fact that GATA can bind DNA in two distinct modes with 
different binding affinity/kinetic stabilities and conformations has important 
implications for transcriptional regulation by this family of proteins. At low expression 
levels, the GATA proteins may preferentially bind to the palindromic sites, and at high 
expression levels, the GATA proteins may be able to bind both palindromic sites and 
single sites, leading to more intra- and interchromosomal interactions, either by 
themselves or through their interaction with cofactors such as the FOG protein. The 
different DNA-bound conformations of GATA proteins may recruit different cofactors 
or change the local chromosomal conformation, leading to different biological 
functions(Chen, Bates et al. 2012). 
 
I.E.3. Physiological Function and Tissue Specificity of GATA-Proteins 
GATA1/2/3 are required for differentiation of mesoderm and ectoderm-derived 
tissues, including the haematopoietic and central nervous system. GATA4/5/6 are 
implicated in development and differentiation of endoderm- and mesoderm-derived 
tissues such as induction of differentiation of embryonic stem cells, cardiovascular 
embryogenesis and guidance of epithelial cell differentiation in the adult.(Lentjes, 
Niessen et al. 2016)(Figure 9). The purification and cloning of GATA-1, ushered in 
studies that elucidated mechanistic principles governing GATA factor function. The 
zinc finger residing closest to the carboxy-terminus (C-finger) mediates sequence-
specific DNA binding to WGATAR motifs, while the zinc finger proximal to the amino-
terminus (N-finger) mediates an important protein–protein interaction with the nine 
zinc finger containing coregulator Friend of GATA-1. The N-finger may also stabilize 
DNA binding in certain contexts. Additional interactions involving the zinc fingers 
have been documented, including binding to the myeloid transcription factor PU.1, 
the erythroid transcription factor ELKF and the mediator complex component Med1. 
Much less is known about the structural basis and biological implications of these 
interactions. The broad GATA-1 N-terminus enhances endogenous target gene 
activation in a context-dependent manner. Missense mutations in the N-terminus 
trigger the usage of an alternative translational start site, yielding a mutant that is 
strongly associated with the development of transient myeloproliferative disease and 
acute megakaryoblastic leukemia. Despite approximately 7 million GATA motifs in 
the human genome, all capable of forming high-affinity complexes with GATA factors 
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and naked DNA in vitro, GATA-1 and GATA-2 occupy only 0.1–1% of these motifs in 
erythroblasts, based on chromatin immunoprecipitation coupled with massively 
parallel sequencing and real-time PCR validation. While the molecular determinants 
for this exquisite discrimination are not fully understood, FOG-1 facilitates GATA-1 
occupancy at a subset of chromatin sites. Genome-wide analysis of cis-elements 
residing at endogenous GATA-1 and GATA-2 occupancy sites led to refinement of 
the GATA consensus from WGATAR to WGATAA. However, the percent of total 
WGATAA motifs occupied remains very low. Beyond GATA motif sequence 
composition, the most rudimentary determinant of chromatin occupancy, diagnostic 
patterns of histone posttranslational modifications demarcate occupied versus 
unoccupied sites, both containing conserved GATA motifs (Figure 10, Principle 1). 
In principle, the unique epigenetic signature of occupied sites may represent primed 
chromatin structures recognized by GATA-1 as a pivotal determinant of site selection. 
Alternatively, the signature may arise as a consequence of GATA-1 chromatin 
occupancy, followed by recruitment of GATA-1 coregulators that modify chromatin 
surrounding the occupancy site. GATA-1 chromatin occupancy leads to either 
activation or repression of target genes, both of which can be mediated by FOG-
1(Figure 10, Principle 2). One mode of FOG-1 function involves interaction of its N-
terminus with the NuRD chromatin remodeling complex, which can mediate both 
repression and activation. GATA-1 utilizes FOG-1 to induce higher order chromatin 
loops, based on chromosome conformation capture (3C) data. In principle, such 
loops can mediate activation or repression, dependent upon the physical relationship 
between the loop and functional features of a gene and the precise nature of the 
structure formed. GATA-1 also recruits the chromatin remodeler BRG1 to chromatin, 
which can mediate higher order looping. Additional GATA-1 mechanisms exist, 
including FOG-1-independent activation and repression, although these mechanisms 
remain poorly understood. GATA-1 commonly co-localizes on chromatin with the 
stem cell leukemia/T-cell acute lymphocytic leukemia-1 (Scl/TAL1) protein, and the 
co-localization commonly correlates with transcriptional activity (Figure 10, Principle 
3). Scl/TAL1 is a master regulator of hematopoiesis that binds E-boxes and non-
DNA-binding components including LMO2, LDB1, ETO2, and single-stranded DNA-
binding proteins. In the context of naked DNA, optimal composite elements that 
support complex formation contain an E-box, a downstream GATA motif, and an 8-bp 
spacer. The 8-bp spacing is crucial for GATA-2-dependent enhancer activity in a 
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transient transfection assay using cells expressing endogenous GATA-2. However, 
GATA-1 and Scl/TAL1 also co-localize at certain chromatin sites lacking composite 
elements. Notably, the additional protein constituents of the complex modulate its 
transcriptional regulatory activity in a context-dependent manner and are linked to the 
development and/or progression of human hematologic malignancies. Sophisticated 
ChIP-seq analyses in the HPC-7 multipotent hematopoietic cell line demonstrated 
that additional components co-localized with GATA-2 and Scl/TAL1. This analysis 
revealed 1015 regions of 200 bp or less in which Scl/TAL1, LYL1, LMO2, GATA-2, 
ERG, FLI-1 and RUNX1 occupancy was detected. As each of these factors is likely to 
engage additional important partners, considerably more work is required to 
understand the structure/function of these higher order chromatin complexes 
containing multiple master regulators of hematopoiesis. GATA factor interplay 
appears to be a common mechanism for controlling developmental processes. 
During the development of erythrocytes, GATA-1 displaces GATA-2 from chromatin 
sites at target genes, and this GATA switch (defined as an exchange of different 
GATA factors at a chromatin site) is tightly coupled to an altered transcriptional 
output (Figure 10, Principle 4). GATA switches were first described at the Gata2 
locus, at which GATA-1 binding instigates repression, thus explaining the differential 
GATA-1 and GATA-2 expression pattern during erythropoiesis. GATA-1 utilizes FOG-
1 to displace GATA-2 from chromatin. The capacity of FOG-1 to bind the NuRD 
complex is required for the GATA switch, as GATA switches were impaired in a 
knock-in mouse strain expressing FOG-1 defective in NuRD complex binding. 
Ectopic FOG-1 expression in mast cell progenitors induces a GATA switch in which 
GATA-1 replaces GATA-2 from the –2.8 kb GATA switch site of the Gata2 locus, 
which was linked to Gata2 repression and generation of erythroid, megakaryocytic 
and granulocytic progeny. During the differentiation of trophoblast giant cells, GATA-
2 displaces GATA-3 at Gata2, which is associated with transcriptional activation. 
Though GATA switches have not been studied in many systems, it is attractive to 
propose that they represent common devices to change transcriptional activity in 
diverse biological contents. Two aspects of the GATA switch paradigm merit careful 
consideration. First, erythroid GATA switches inform us that different GATA factors 
can exert qualitatively distinct functions through an identical chromatin site; one 
GATA factor mediates target gene activation, while the other confers repression or 
vice versa. Thus, while different GATA factors share certain biochemical attributes, 
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including their highly conserved zinc finger module, intrinsic differences underlie the 
qualitatively distinct activities. A notable difference is the relative high and low 
stabilities of GATA-1 and GATA-2, respectively. As proteasome inhibition stabilizes 
GATA-2 and blocks GATA switches, the low stability appears to be an important 
determinant of GATA switches. Another important implication of the GATA switch 
paradigm is that GATA switches and the requisite factors/signals that control the 
switches represent a novel tool to control developmental processes. Since certain 
non-hematopoietic cell types can express multiple GATA factors, it would not be 
surprising if the erythroid GATA switch mechanism were applicable to non-
hematopoietic contexts. Despite major progress in elucidating GATA factor 
mechanistic principles, many questions remain unanswered regarding how cellular 
signaling pathways dynamically control GATA factor activities and GATA factor 
dependent biological processes. In summary, GATA factor mechanistic principles 
(Figure 10) include: (1) GATA factors target a small subset of chromatin sites 
containing a cis-element with the consensus sequence WGATAA; (2) GATA-1 
activates or represses target genes in a FOG-1-dependent or –independent manner; 
(3) GATA-1 and GATA-2 commonly co-occupy chromatin sites with Scl/TAL1, and 
members of the Scl/TAL1 complex promote or suppress GATA factor-regulated 
transcription in a context-dependent manner; and (4) GATA switches can involve 
qualitatively distinct activities of different GATA factors through an identical chromatin 
site(Bresnick et al. 2012) 
 
54 
 
 
 
Figure 9 Distribution of GATA expression in various organs during vertebrate development. The 
expression of all GATA factors is depicted in the corresponding tissues. The distribution of the 
expression patterns roughly reflects the two GATA subgroups (GATA1/2/3 versus GATA4/5/6). 
(Lentjes et al., 2016) 
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Figure 10 GATA factor mechanistic principles. The models depict mechanistic principles derived from 
studies of GATA-1 and GATA-2. While the fundamental nature of these principles is likely to be shared 
by other GATA factors, additional GATA factor-specific mechanistic permutations are expected. 
(Bresnick, Katsumura et al. 2012) 
 
 
 
I.E.4. Specificity in the Regulation of Transcription by GATA Factors 
The importance of GATA factors for development is illustrated by the embryonic 
lethality of most single GATA knockout mice. Moreover, GATA gene mutations have 
been described in relation to several human diseases, such as hypoparathyroidism, 
sensorineural deafness and renal insufficiency (HDR) syndrome, congenital heart 
diseases (CHDs) and cancer. GATA family members are emerging as potential 
biomarkers, for instance for the risk prediction of developing acute megalokaryblastic 
leakemia in Down syndrome and for the detection of colorectal- and breast 
cancer.(Lentjes, Niessen et al. 2016) 
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I.E.4.1. Post-translational Modifications 
Chromosomal alterations as well as regulation of GATA genes and proteins on 
transcriptional and post-transcriptional levels can also contribute to disease 
development. Recently it has been shown that combined tet methylcytosine 
dioxygenase 2 (TET2) and fms related tyrosine kinase 3 (FLT3) mutations regulate 
epigenetic silencing of GATA2 by promotor hypermethylation in human AML. In clear 
cell renal cell carcinomas downregulation of GATA3 expression by promoter 
hypermethylation results in decreased expression of TbetaRIII, a protein with tumour 
suppressor features, during disease progression . Presence of suppressive histone 
(H3K27) trimethylation of GATA3 together with absence of the GATA3 protein in 
anaplastic large cell lymphoma implicates epigenetical contribution in the 
pathogenesis of this disease. Clues about the transcriptional regulation of the GATA4 
and GATA6 genes come from a SUMO-specific protease 2 (SENP2) knockout model. 
These mice have reduced expression of GATA4 and GATA6 and defects in the 
embryonic heart. In SENP2 deficient embryos sumoylation of CBX4, accumulates 
and occupies the promoters of GATA4 and GATA6, thereby leading to transcriptional 
repression. GATA4 is located at chromosome 8p, a chromosomal locus frequently 
deleted in multiple tumour types such as colorectal and oesophageal cancer. 
Alternatively GATA4 can be downregulated via epigenetic silencing, such as 
hypoacetylation of histones H3 and H4 and promoter CpG island hypermethylation, 
which has been observed in colorectal, gastric, oesophageal, lung, ovarian and HPV-
driven oropharyngeal cancer, in GBM and in diffuse large B-cell lymphoma. In 
contrast, GATA4 amplification is recently described in certain gastric cancer which 
indicates a more oncogenic function. Further studies are needed to unravel the 
molecular mechanisms of GATA4 amplified in comparison with GATA4 methylated 
gastric cancers. GATA5 is located at chromosome 20q13, a locus which is often 
amplified and methylated in multiple cancer types. No coding sequence mutations in 
GATA4 and GATA5 have been described so far in colorectal- and breast cancer. 
However, promoter methylation of GATA5 might be established in order to 
downregulate increased gene expression imposed by amplification. Identified post-
transcriptional modifications on GATA proteins include acetylation, phosphorylation 
and methylation. Protein stability of GATA2 and GATA3 is regulated by 
phosphorylation and ubiquitilation. Phosphorylation of GATA3 by respectively Cyclin-
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dependent kinase 1 (CDK1) and CDK2 was required for F-box/ WD repeat-containing 
protein 7 (Fbw)-7 mediated ubiquitilation and degradation and contributed to precise 
differentiation of HSCs and T-cell lineages. How GATA acetylation influences 
transcriptional processes has been investigated for GATA1. It turns out that 
bromodomain protein Brd3 binds to acetylated GATA1 to regulate the chromatin 
occupancy at erythroid target genes. For GATA4 post-transciptional modifications 
have mainly been studied in the context of hypertrophy of the heart. Activation of 
GATA4 occurs in part through acetylation by the transcriptional coactivator p300. 
Takaya et al. identified 4 GATA4 lysine residues that, when mutated, lacked p300-
induced acetylation, DNA binding and transcriptional activities. Phosphorylation of 
p300 by Cdk9 increases the ability of p300 to induce acetylation and DNA binding of 
GATA4. Alternatively, phosphorylation of GATA4 on serine 105 is critical for a 
productive cardiac hypertrophic response to stress stimulation in adult mice. 
Deacetylation of GATA4, and subsequent suppression of transcriptional activation, is 
mediated by histone deacetylase 2 (HDAC2) and the small homeodomain factor 
Hopx. Recently it was reported that the GATA4 protein is methylated by Polycomb-
repressive complex 2 member Ezh2. This reduced the interaction with and 
acetylation by p300, thereby reducing GATA4’s transcriptional activity. Together, this 
emphasises how important post-transciptional modifications are for the regulation of 
GATA activity.(Lentjes, Niessen et al. 2016) 
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Aim Of The Thesis 
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II AIM OF THE STUDY 
 
The Na+-Ca2+ exchanger 3 (NCX3) is a plasmamembrane protein important for the 
cellular regulation of calcium and sodium homeostasis and is exclusively expresses 
in the brain and skeletal muscle (Annunziato et al. 2004a)). Several studies 
demonstrated that ncx3 silencing:(1) increased the infarct volume size after brain 
ischemia  (Pignataro et al. 2004a; Molinaro et al. 2008)(Pignataro et al., 2004; Boscia 
et al., 2006; Molinaro et al., 2008), (2) partially reverted the 
preconditioning/postconditioning-induced neuroprotection (Pignataro et al., 2009; 
Pignataro et al., 2011b; Pignataro et al., 2011a) (3) caused an impairment in 
hippocampal long-term potentiation and in spatial learning and memory (Molinaro et 
al., 2011), (4) determined in in vitro model of Alzheimer Disease a hyperfunctional 
form delays caspase-12 activation and consequent neuronal death (Pannaccione et 
al., 2012). At transcriptional level it has been demonstrated that ncx3 mRNA 
expression is up-regulated by the transcriptional activator adenosine 3',5' cyclic 
monophosphate (cAMP) response element binding protein (CREB) (Gabellini et al., 
2003) and is down-regulated by the transcriptional repressor downstream regulatory 
element antagonistic modulator DREAM (Gomez-Villafuertes et al., 2005) via a 
genetic mechanism . Interestingly, the ncx3 promoter (ncx3-pr) sequence contains 
several transcription factors (TF) motives, such as for the Early growth response 
protein 1 (EGR1), GATA transcription factors 1, 2 and 3 (GATA1, GATA2 and 
GATA3) and specificity protein 1, 3 and 4 (Sp1, Sp3 and Sp4) (Gabellini, 2004). 
Since until now only few papers have specifically studied the transcriptional 
regulation of ncx3 in the brain (Pignataro et al., 2009; Formisano et al., 2015), we 
investigated the role of above mentioned TF to modulate ncx3. Interestingly, among 
all the TF studied only GATA3 increased ncx3 expression. Then, we revealed the 
presence of sensitive GATA elements on the ncx3 brain promoter and the specificity 
of GATA3 to bind this sequence. In addition, because GATA3 regulates its target 
gene by modulating the methylation status of the histone 3 lysine 4 (H3K4me) (Wei 
et al., 2011), we investigated whether the GATA3 and the histone-lysine N-
methyltransferase 2A (KMT2A) that is a H3K4-specific methyltransferase 
(Jakovcevski et al., 2015) form a complex able of activating ncx3 in in vivo model of 
brain ischemic preconditioning. 
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III. MATERIALS AND METHODS 
 
III.1. Materials  
Luciferase reporter kits and luciferase vectors were from Promega (Milan, IT). 
Synthetic oligonucleotides were from Primm (Milan, IT). siRNAs for GATA3 
(siGATA3) (sc-61845) was from Santa Cruz Biotechnology, INC. this compound was 
dissolved in dimethyl sulfoxide (DMSO) and diluted before application to a final 
DMSO concentration lower than 0.2%. All common reagents were of the highest 
quality and were purchased from Sigma (Milan, IT). 
 
III.2. Primary Cortical Neurons 
Primary cortical neurons were prepared from 17-day-old Wistar rat embryos (Charles 
River, Calco, IT) and used after 7 days. Cytosine arabinoside (2.5 μM) was added 
the second day to reduce glial contamination. The experiments on primary cortical 
neurons were performed according the procedures described in experimental 
protocols approved by Ethical Committee of the “Federico II” University of Naples. 
Briefly, dissection and dissociation were performed in Ca2+/Mg2+-free phosphate-
buffered saline (PBS) containing glucose (30 mM/l). Tissues were incubated with 
papain for 10 minutes at 37°C and dissociated by trituration in Earl’s Balanced Salt 
Solution (EBSS) containing DNAse (0,16 U/ml), bovine serum albumin (10 mg/ml), 
and ovomucoid (10 mg/ml). Neurons were plated in plastic Petri dishes (Falcon™ 
Becton-Dickinson, Buccinasco, IT) pre-coated with poly-D-lysine (20 µg/ml), were 
grown in MEM/F12 containing glucose, 5% of deactivated fetal bovine serum (FBS) 
and 5% of horse serum (HS), glutamine (2 mM/l), penicillin (50 Units/ml), and 
streptomycin (50 μg/ml) (Invitrogen, Milan, IT). Cell density was 2x106 cells/well for 
12-well plate for luciferase assay, 5x106 cells/well for 60 mm for qRT-PCR and 
15x106 cells/well for 100 mm for Western Blot analysis, ChIP analysis and re-ChiP. 
 
III.3. Transfection with Expression Plasmids or Small Interfering RNA (siRNA) 
and Luciferase Reporter Assay, in Cortical Neurons  
Cortical neurons were transfected with 50nM of negative control siRNA (siCTL) and 
50nM of siRNA specific for GATA3 (siGATA3). To overexpress AP-2, EGR1, GATA1, 
62 
 
GATA2, GATA3 and Sp4 neurons were transfected with above mentioned constructs 
in the following amounts: 1.3 μg for 12-well plates, 7 μg for 60 mm plates and 15 μg 
for 100 mm plates. Each transfection was performed at 5 DIV in Optimem with 
Lipofectamine LTX (15338-100, Invitrogen, Milan, IT), as suggested by the producer. 
After 2 hours transfection mix was replaced with fresh medium. For luciferase assay 
experiments, cortical neurons were transfected in 12-well plates. Cells were co-
transfected with 1 μg of total DNA vectors; the reporters (560 ng each) were the 
following: (1) the pGL3basic construct, (2) the pGL3-ncx3, that contains 500bp of the 
ncx3 brain promoter, (3) the pGL3-ncx3/GATA3mut, that contains a mutation in 
GATA binding site of ncx3 brain promoter. Mutagenesis of the GATA3 sites in the 
promoter was performed by using the QuickChange site-directed mutagenesis kit 
from Stratagene. Each transfection mix also contained 200 ng of the pRL-TK control 
vector expressing renilla luciferase gene. After 24hours of transfection lysates were 
analyzed with Dual-Luciferase Reporter Assay System kit (E1910) (Promega, Milan, 
IT), as already reported) (Formisano et al. 2013). 
 
III.4. Quantitative Real-Time PCR (qRT-PCR) Analysis 
The first-strand cDNA and quantitative real-time PCR was carried out as previously 
described (Formisano et al. 2007; Formisano, Guida et al. 2013). Using 1/10 of the 
cDNAs as a template, the quantitative real-time PCR was carried out in a 7500 fast 
real-time PCR system (Applied Biosystems, Monza, IT) by Fast SYBR Green Master 
Mix (cod. 4385610; Applied Biosystems, Monza, IT). Samples were amplified 
simultaneously in triplicate in one assay as follows: heating 2 min @ 50º C, 
denaturation 10 min @ 95º C, amplification and quantification 35 cycles of 15 sec @ 
95º C, 1 min @ 60º C with a single fluorescence measurement. PCR data was 
collected using ABI Prism 7000 SDS software (Applied Biosystems). Normalization of 
the data was performed by HPRT as an internal control. Differences in mRNA 
content between groups were calculated as normalized values by using 2-ΔΔct 
formula and results were tested for significance using Relative Expression Software 
Tool (REST ©)(Formisano, Noh et al. 2007). The oligonucleotide sequences for 
NCX3 and Hypoxanthine phosphoribosyl-transferase (HPRT) were already published 
(Pignataro et al., 2011b; Formisano et al., 2012). 
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III.5. Western Blotting 
For Western blot analysis, cells or tissues were collected in ice-cold lysis buffer 
(Formisano, Guida et al. 2013) containing anti-protease cocktail (P8340 Sigma, 
Milan, IT). For NCX3, GATA3 and KMT2A expression, proteins (100 µg) were 
separated on 8% SDS polyacrylamide gels. Both were transferred onto Hybond ECL 
nitrocellulose membranes (Amersham, Milan, IT). Membranes were blocked with 5% 
non fat dry milk in 0.1% Tween 20 (Sigma, Milan, IT) (2 mM Tris-HCl and 50 mM 
NaCl pH 7.5) for 2 hours at room temperature, and then they were incubated 
overnight at 4°C in the blocking buffer with the 1:250 monoclonal antibodies against 
GATA3 (sc-268) and KMT2A (sc-374392) (Santa Cruz Biotechnology, INC), 1:1000 
monoclonal antibodies against NCX-3 (Swant, Bellinzona, Switzerland) 1:1000 β-
actin (A 4700) (Sigma, Milan, IT), 1:15000 α-tubulin (Sigma, Milan, IT). Finally, after 
the incubation with primary antibodies, membranes were washed with 0.1% Tween 
20, followed by incubation with secondary antibodies for 1 h at room temperature. 
Immunoreactive bands were detected with the ECL reagent (Amersham). The optical 
density of the bands, normalized to β-actin or tubulin, was determined by Chemi-Doc 
Imaging System (Bio-Rad, Hercules, CA). 
 
III.6. Chromatin Immunoprecipitation (ChIP) and Re-Chip Assay 
Brain tissue and cortical neurons were processed into chromatin by use of published 
protocols (Formisano et al., 2007; Formisano et al., 2012) with some modifications. 
Cells and tissues were cross-linked with 1% formaldehyde, and then reaction was 
stopped by adding glycine to a final concentration of 0.125 M. Brain tissue and cells 
were washed three times in cold PBS containing proteinase inhibitors and then 
collected in a buffer containing: 50mM Tris pH 8.1, 1% SDS, 10 mM EDTA, and anti-
protease cocktail. For cell and tissue samples, chromatin was fragmented by 
sonication into 200–500 bp fragments (6 rounds for cells and 15 rounds for brain 
tissue of 15 1-s pulses at 50% of maximum potency) by a Bandelin Sonopuls HD 
2070 ultrasonic homogenizer (Bandelin, Berlin, Germany). Equal amounts of 
chromatin lysates (50 μg for cells and 70 μg for tissues) were incubated overnight 
with 3μg of antibody for GATA3 (sc-268) and KMT2A (sc-374392) (Santa Cruz 
Biotechnology,INC), Tri-Methyl-Histone H3(Lys4) (17420, Thermo Fisher Scientific), 
acetyl-Histone H4 (06-866, MERCK) and RNA POL II (R1530, Sigma, Milan, IT). 
After immunoprecipitation, the DNA-histone complex was collected with 40 μl of 
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salmon sperm DNA/protein A- or G-agarose beads for 2 hours (16-157, 16-201) 
(Millipore, Milan, IT). After rotating for 2 hours at 4°C on a spinning wheel, the beads 
were washed once with each of the following buffers in the order shown: high-salt 
buffer (0.1% SDS, 1% Triton, 2mM EDTA, 20mM Tris HCl pH 8.1, 500 mM NaCl); 
low-salt buffer (0.1% SDS, 1% Triton, 2mM EDTA, 20mM Tris HCl pH 8.1, 150mM 
NaCl); LiCl buffer (0.25M LiCl, 1% NP40, 1% deoxycholate, 1mM EDTA, 10mM Tris 
HCl pH 8.1), and with TE buffer two times at room temperature (10mM Tris pH 8.1 
and 1mM EDTA). The precipitated fragments were eluted with a buffer containing 1% 
SDS and 0.1M NaHCO3. DNA was analyzed by qRT-PCR using Fast SYBR Green 
Master Mix (cod 4385610; Applied Biosystems, Milan, IT). Heating 2 min @ 50ºC, 
denaturation 10 min @ 95ºC, amplification and quantification 35 cycles of 30 sec @ 
95ºC; 1 min @ 60°C with a single fluorescence measurement. The binding activity 
was graphically represented as the percentage of total input of chromatin and the 
results were analyzed using a previously described formula (Renthal et al., 2007). 
The following oligonucleotides were used for the amplification of immunoprecipitated 
DNA: ncx3-Br Forward 5’-AGCACGGACCTAGCGTTCA-3’ and Reverse 5’- 
GGGCTTGCATCCGCATT -3’, ncx3-Br Forward 5’-
GGGTGCAGAAGAGAGCGCTGGC-3’ and Reverse 5’- 
GCACAAAGCGCGGCGGCCCG-3’. For each amplification, melting curves and gel 
electrophoresis of the PCR product were used to verify their identities. Samples were 
amplified simultaneously in triplicate in one assay run. Re-ChIP experiments were 
employed to detect the simultaneous presence of GATA3 or KMT2A, respectively. 
Beads from the first ChIP with anti-GATA3 and anti-KMT2A were incubated with an 
equal volume of 10 nM dithiothreitol at 37 °C for 30 min, centrifuged at 12000 rpm for 
1 min to elute DNA-bound proteins. The elution was repeated twice. The final elute 
was diluted 1:10 in lysis buffer containing a protease inhibitor cocktail and re-
immunoprecipitated with the anti-KMT2A, the anti-GATA3 antibodies. ChIP and input 
DNA were analyzed by PCR. Denaturation 10 min @ 95ºC, 35 cycles of 30 sec @ 
95ºC; 1 min @ 60ºC; 1 min @ 72ºC. The PCR products were electrophoresed on a 
1.5% agarose gel and stained with ethidium bromide. For ChIP and Re-ChIP 
experiments we used ncx3-Br primers, since the amplified sequence of ncx3-Br 
contains the binding sites forGATA3, whereas as negative control were used primers 
binding ncx1 promoter region already tested (Formisano et al. 2015). 
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III.7. In Vivo Studies 
 
III.7.1. Experimental Groups 
Male Sprague-Dawley rats (Charles River) weighing 250 to 300 g were housed under 
diurnal lighting conditions (12 h darkness/light). Experiments were performed 
according to the international guidelines for animal research. All experiments were 
approved by the Institutional Animal Care and Use Committee of the “Federico II” 
University of Naples, IT. 
 
III.7.2. Transient Focal Ischemia and Ischemic Preconditioning 
Transient focal ischemia was induced as previously described (Valsecchi et al. 
2011), by suture occlusion of the middle cerebral artery (MCA) in male rats 
anesthetized using 1.5% sevoflurane, 70% N2O, and 28.5% O2. Achievement of 
ischemia was confirmed by monitoring regional cerebral blood flow through laser 
Doppler (PF5001; Perimed). Animals not showing a cerebral blood flow reduction of 
at least 70% were excluded from the study. Animals that did not show a cerebral 
blood flow reduction of at least 70% were excluded from the experimental group, as 
well as animals that died after ischemia induction. Rats were divided into 4 
experimental groups: (1) sham-operated rats (Sham); (2) preconditioned rats (PC); 
(3) ischemic rats, subjected to transient MCA occlusion (tMCAO); and (4) 
preconditioned ischemic rats (PC+tMCAO). The sham-operated animals underwent 
the same experimental conditions except that the filament was not introduced; in the 
ischemic group, the MCA was occluded for 100 minutes; in the preconditioned 
ischemic group, rats were subjected to 30 minutes of tMCAO 72 hours before of 100 
minutes of tMCAO. All animals were euthanized 24 h after the 100 min tMCAO. 
Rectal temperature was maintained at 37±0.5°C with a thermostatically controlled 
heating pad and a catheter was inserted into the femoral artery to measure arterial 
blood gases before and after ischemia (Rapid Laboratory 860, Chiron Diagnostic). All 
surgical procedures were performed under an operating stereomicroscope. 
 
III.8. Statistical Analysis 
The data were evaluated as means ± SEM. Statistically significant differences among 
means were determined by ANOVA followed by Student-Newman-Keuls test. The 
threshold for statistical significance data was set at p<0.05 
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IV.RESULTS 
IV.1.GATA3 Binds and Activates ncx3 by a Specific GATA Sequence  
NCX3 human gene promoter contains binding sites for the following transcription 
factors: activator protein-2 (AP-2), Early growth response protein 1 (EGR1), GATA 
transcription factors 1, 2 and 3 (GATA1, GATA2 and GATA3) and Specificity protein 
1, 3 and 4 (Sp1, Sp3 and Sp4) (Gabellini 2004). To evaluate the role of these 
transcription factors on the ncx3 gene promoter activity, primary cortical neurons 
were co-transfected with vectors overexpressing AP-2, EGR1, GATA1, GATA2, 
GATA3 and Sp4, and with the pGL3basic construct enclosing the 650 bp genomic 
fragment containing the minimal ncx3 promoter region and exon 1-flanking region 
upstream of the ncx3 exon1 gene (pGL3-ncx3), previously used (Gomez-Villafuertes 
et al. 2005). Importantly, these constructs increased AP-2, EGR1, GATA1, GATA2, 
GATA3 and Sp4 mRNA expression by 177.1%, 122.46%, 119.35%, 113.03%, 
103.97% and 93.38%, respectively (Figs.1 A–F).  
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Figure 1 Cortical neurons transfected with constructs for AP-2, EGR1, GATA1, GATA2, GATA3 and Sp4.  
 
(A–F), qRT-PCR of AP-2, EGR1, GATA1, GATA2, GATA3 and Sp4 genes in transiently transfected neurons with 
Empty Vector and AP-2, EGR1, GATA1, GATA2, GATA3 and Sp4 constructs. Graphs show the quantification of 
the ratio of AP-2, EGR1, GATA1, GATA2, GATA3 and Sp4 to HPRT. Bars represent mean ± S.E.M. n = 3 per 
group. *p ≤ 0.05 versus EV. 
 
As shown in the Luciferase Assay represented in Figure 2 A, only GATA3 
overexpression significantly increased ncx3 gene promoter activity. Additionally, a 
new construct consisting in ncx3-pr containing a mutation in the GATA binding site 
induced by site direct mutagenesis was generated (pGL3-ncx3 GATA3mut). 
Cotransfection of pGL3-ncx3 GATA3mut into cortical neurons with an expression 
plasmid of GATA3 did not increase ncx3 promoter activity (Fig. 2B). Moreover, we 
performed a ChIP analysis in PC12 cells that demonstrated that the binding of 
GATA3 on its specific sequence on ncx3 brain promoter significantly increased in cell 
overexpressing GATA3 (Fig. 2C).These results indicate that GATA3 increased ncx3 
gene promoter activity in a sequence specific manner. 
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Fig 2 GATA3 binds GATA sequence on ncx3 promoter.  
(A) Luciferase activity of cortical neurons cotransfected with pGL3 basic, pGL3-ncx3 alone or with AP2, EGR, 
GATA1, GATA2, GATA3 and Sp4 constructs. Bars represent mean ± S.E.M. n = 3 per group. *p ≤ 0.05 versus , 
pGL3-ncx3. (B) ChIP analysis of the ncx3 promoter containing the GATA/ncx3 region performed with anti-GATA3. 
The binding activity of GATA3 is graphically represented as the percentage of total input of chromatin DNA. Bars 
represent mean ± S.E.M. n = 3 per group. *p ≤ 0.05 versus EV. (C) Luciferase activity of cortical neurons 
cotransfected with the following constructs: (1) pGL3 basic, (2) pGL3-ncx3, (3) pGL3-ncx3 + Empty vector, (4) 
pGL3-ncx3 + GATA3 and (5) pGL3-ncx3 Mut + GATA3. Bars represent mean ± S.E.M. n = 3 per group. *p ≤ 0.05 
versus , pGL3-ncx3 and ^ p ≤ 0.05 versus , pGL3-ncx3 + GATA3. 
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Next, transfection of specific siRNAs for GATA3 (siGATA3) reduced its protein 
expression by 42.73% (Fig. 3A). Interestingly, siGATA3 significantly reduced ncx3 
mRNA and protein expression (Figs. 3B, C), indicating that GATA3 is a ncx3 gene 
activator. 
Fig 3 GATA3 silencing reduces NCX3 mRNA and protein levels in primary cortical neurons.  
(A,B) Representative WB with quantification of GATA3 and NCX3 transfection with siCTL or siGATA3. Graphs 
show the quantification of the ratio of GATA3 and NCX3 to Tubulin. Bars represent mean ± S.E.M. n = 3-4 per 
group. *p ≤ 0.05 versus siCTL. (C) qRT-PCR of NCX3 gene in transiently transfected neurons with siCTL and 
siGATA3 constructs. Graphs show the quantification of the ratio of GATA3 to HPRT. Bars represent mean ± 
S.E.M. n = 3 per group. *p ≤ 0.05 versus siCTL 
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Coherently, neurons overexpressing GATA3 increased its protein expression by 
42.73% (Fig. 4A), and significantly increased NCX3 mRNA and protein expression 
(Figs. 4B,C). These experiments confirm that GATA3 up-regulated ncx3 gene at 
transcriptional level. 
 
Fig 4 GATA3 overexpression up-regulates NCX3 mRNA and protein levels in primary cortical neurons.  
(A,B) Representative WB with quantification of GATA3 and NCX3 transfection with an empty vector or with a 
construct overexpressing GATA3. Graphs show the quantification of the ratio of GATA3 and NCX3 to Tubulin. 
Bars represent mean ± S.E.M. n = 3 per group. *p ≤ 0.05 versus Empty Vector. (C) qRT-PCR of NCX3 gene in 
transiently transfected neurons with empty vector and GATA3 constructs. Graphs show the quantification of the 
ratio of GATA3 to HPRT. Bars represent mean ± S.E.M. n = 3 per group. *p ≤ 0.05 versus Empty Vector. 
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IV.2. GATA3, KMT2A and NCX3 Increase in the Temporoparietal Cortex After 
Preconditioning+Ischemia 
 
Because ncx3 gene and protein are increased in an in vivo model of brain ischemic 
Preconditioning(Formisano, Guida et al. 2015) and GATA3 activates its target genes 
by increasing the levels of the lysine 4 tri-methylation of histone H3 (H3K4me3) (Wei 
et al. 2011), an epigenetic modification catalyzed by the histone methyl transferase 
2A (KMT2A) enzyme, that is basically expressed in the brain (Jakovcevski et al. 
2015), we studied in the temporoparietal cortex of rats subjected to 
Preconditioning+Ischemia (PC+tMCAO) GATA3, KMT2A and NCX3 protein 
expression. Western blot analysis revealed that PC+tMCAO after 12 and 24 hours 
increases the expression of GATA3 and KMT2A and returns to sham level at 48 and 
72 hours (Figs.5 A, B). Interestingly, NCX3 protein expression levels increased 24, 
48 and 72 hours after PC+tMCAO, compared with the sham (Fig. 5D). On the 
contrary, ncx3 gene increased in a time dependent manner at 12 and 24 hours, but it 
did not modify at 48 and 72 hours after PC+tMCAO, compared to sham (Fig. 5C).  
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Fig 5 Expression levels of GATA3, KMT2A and NCX3 protein expression and ncx3 gene after 12, 24, 48 
and 72 hours of PC+tMCAO 
(A,B,D) Representative WB with quantification of GATA3, KMT2A and NCX3 in the rat ipsilateral–temporoparietal 
cortex in Sham and PC+tMCAO groups. Graphs show the quantification of the ratio of GATA3, KMT2A and NCX3 
to Tubulin. Bars represent mean ± S.E.M. n = 4 per group. *p ≤ 0.05 versus Sham, ^ p ≤ 0.05 versus 12 hours of 
PC+tMCAO and ^^ p ≤ 0.05 versus 12 and 24 hours of PC+tMCAO. (C) qRT-PCR of NCX3 gene in the rat 
ipsilateral–temporoparietal cortex in Sham and PC+tMCAO groups. Graphs show the quantification of the ratio of 
NCX3 to HPRT. Bars represent mean ± S.E.M. n = 4 per group. *p ≤ 0.05 versus Sham , ^ p ≤ 0.05 versus 12 
hours of PC+tMCAO and ^^ p ≤ 0.05 versus 12 and 24 hours of PC+tMCAO. 
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IV.3. GATA3, KMT2A and NCX3 Increase in the Temporoparietal Cortex After, 
Preconditioning, and Preconditioning+Ischemia but not After Ischemia 
 
In the ipsilesional-temporoparietal cortex, GATA3, KMT2A and NCX3 protein 
expression significantly increased after 24 hours of preconditioning alone (PC), or 
after PC+tMCAO. Interestingly, western blot after 24 hours of tMCAO revealed a 
reduction of NCX3, but not of GATA3 and KMT2A protein expression (Figs.6 A-C). 
To identify the possible interaction between GATA3 and KMT2A, their binding activity 
to the ncx3 promoter sequence was evaluated in rats subjected to tMCAO and 
PC+tMCAO by Re-ChIP experiments. As shown in figures 6 D and E chromatin from 
Sham, tMCAO, PC and PC+tMCAO groups was sequentially immunoprecipitated 
with GATA3 and KMT2A antibodies (Fig. 6 D), or conversely, with KMT2A antibody 
followed by GATA3 antibody (Fig. 6 E). Real‐time PCR experiments identified the 
colocalization of GATA3 and KMT2A on the ncx3 promoter gene (Figs. 6 D, E). 
These results demonstrate that the binding between GATA3/KMT2A on ncx3 
promoter increased after PC and PC+tMCAO 
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Fig 6 Protein levels of GATA3, KMT2A and NCX3 and GATA3/KMT2A colocalization on ncx3-Br in the 
ipsilateral–temporoparietal cortex after 24 hours of tMCAO, PC and PC+tMCAO 
(A-C) Representative WB with quantification of GATA3, KMT2A and NCX3 in the rat ipsilateral–temporoparietal 
cortex in: (1) Sham, (2) tMCAO, (3) Preconditining alone (PC) and (4) PC+tMCAO groups. Graphs show the 
quantification of the ratio of GATA3, KMT2A and NCX3 to Tubulin. Bars represent mean ± S.E.M. n = 3 per group. 
Figure 6A *p ≤ 0.05 versus Sham, **p ≤ 0.05 versus Sham and tMCAO and ***p ≤ 0.05 versus all; Figure 6B *p ≤ 
0.05 versus Sham, **p ≤ 0.05 versus Sham and tMCAO; Figure 6C **p ≤ 0.05 versus Sham and tMCAO and ***p 
≤ 0.05 versus all. (D-E) Re-ChIP analysis of ncx3-pr in the ipsilateral–temporoparietal cortex in (1) Sham, (2) 
tMCAO, (3) Preconditining alone (PC) and (4) PC+tMCAO groups. Primary ChIP products for anti-GATA3 (1° Ab) 
were subjected to re-ChIP with anti-KMT2A (2° Ab). The binding activity of GATA3 and KMT2a is graphically 
represented as the percentage of total input of chromatin DNA. Bars represent mean ± S.E.M. n = 3 per group. *p 
≤ 0.05 versus Sham and tMCAO. 
 
Specifically, it is known that the transcription factor GATA3 regulates its target gene 
by histone lysine acetylation (Fields et al. 2002) and methylation(Wei, Abraham et al. 
2011), that are both marker of transcriptional activation. Therefore, through 
experiments of ChIP assay, we studied the modification of the: (1) acetylated histone 
protein H4, (2) tri-methylated lysine 4 histone protein H3 and (3) the binding of RNA 
polymerase II (RNA-Pol II) on ncx3 promoter sequence in the ipsilesional–
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temporoparietal cortex of rats subjected to tMCAO, PC and PC+tMCAO and 
compared it with Sham. We found that tMCAO reduced the amount of the ncx3 
promoter associated with acetylated histone H4 and RNA-Pol II (Figs. 7A, C), but did 
not significantly alter the trimethylation status of residue K4 of histone H3 (Fig. 7B). 
Notably, ncx3 promoter association with acetylated H4 was not significantly modified 
by PC only and PC+tMCAO (Fig. 7A). On the other hand, PC+tMCAO increased 
H3K4me3 binding on ncx3 promoter sequence, in parallel with an increased amount 
of the ncx3 promoter associated with RNA-Pol II (Fig. 7B, C). Altogether, these 
results demonstrate that after PC and PC+tMCAO, GATA3 and H3K4 increase their 
binding on ncx3 determining an increase of ncx3 transcription 
 
 
Fig 7 Effect of tMCAO and PC+tMCAO rat models on H4 acetylation, , H3-K4me3 and RNA-Pol II to ncx3-Br 
(A-C) ChIP analysis of ncx3-pr in the ipsilateral–temporoparietal cortex in: (1) Sham, (2) tMCAO, (3) 
Preconditining alone (PC) and (4) PC+tMCAO groups. The binding activity of H4 acetylation (H4 acetyl), H3-
K4me3 and RNA-Pol II is graphically represented as the percentage of total input of chromatin DNA. Each column 
represents the mean SEM (n = 3 per group. Figure 7A *p ≤ 0.05 versus Sham; Figure 7B *p ≤ 0.05 versus 
Sham and tMCAO; Figure 7C *p ≤ 0.05 versus Sham and tMCAO and **p ≤ 0.05 versus all 
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V. DISCUSSION 
This work demonstrated that NCX3 is epigenetically increased in brain ischemic 
preconditioning by GATA3/KMT2A complex. Specifically, our findings indicate that 
these proteins form a transcriptional complex on the ncx3-pr sequence in brain 
ischemic preconditioning. Particularly, 24 hours after PC+tMCAO was the time point 
in which GATA3 and KMT2A protein and ncx3 mRNA arised the maximum increase. 
Furthermore, we found that ncx3 is a new GATA3 target gene. Indeed, GATA3 
selectively activates neuronal NCX3 expression via GATA sequence. Interestingly , 
ncx3-GATA sequence on human genome is located on the Chr6:105.098.530-
105.098.539, and has 100% interspecies homology between human, rat and mouse 
(Fig. 8). Interestingly, site-direct mutagenesis studies on ncx3-GATA3 sequence in 
cortical neurons totally blocked GATA3 effect on the activation of NCX3, due to a 
reduced GATA3 binding to the ncx3 promoter sequence. Moreover, GATA3, as 
occurred for NCX3, is neuroprotective, as evidenced by the fact that its expression is 
required for maintaining neuronal sympathetic survival (Tsarovina et al., 2010). By 
ChIP experiments we found that the transcriptional activator GATA3, by recruiting the 
epigenetic writer KMT2A, forms a complex upregulating ncx3 in an in vivo model of 
brain ischemic preconditioning. Interestingly, neuronal ablation of KMT2A, in mouse 
post-natal forebrain and adult prefrontal cortex (PFC) is associated with increased 
anxiety and robust cognitive deficits without locomotor dysfunction (Jakovcevski, 
Ruan et al. 2015). Regarding the mechanism by which GATA3 regulates its target 
gene it has been reported that in lymphoid cells it facilitates both H3K4me1 and 
H3K4me2, as well as H3K27me3 at enhancers to mediate gene activation and 
repression, respectively (Wei, Abraham et al. 2011). The results of the present study 
for the first time identified that the specific mechanism by which the transcription 
factor GATA3 increased its target gene ncx3 involves histone lysine methylation 
through KMT2A. Ischemic preconditioning promotes association of GATA3 and 
KMT2A on ncx3 brain promoter sequence in the temporoparietal cortex, in 
accordance with a casual relation between GATA3 and KMT2A induction and ncx3 
up-regulation. We further show that PC+tMCAO promotes an increased 
trimethylation of H3-K4 (index of gene activation), in parallel with an increased 
binding of the RNA Pol II to the ncx3 promoter sequence, an epigenetic signature of 
gene activation. Furthermore, H4 acetylation was reduced in tMCAO group, but not in 
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PC+tMCAO group, indicating that lysine methylation and acetylation are not 
associated and that methylation occurred in the exclusively preconditioning phase 
and acetylation only after stroke.  
 
 
Fig 8 Alignment GATA3 consensus sequence on NCX3 Promoter in Human/Rat/Mouse  
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VI. CONCLUSIONS 
 
Collectively, these findings identify that the transcriptional activator GATA3, by 
recruiting KMT2A, up-regulates NCX3 in the brain through an increase of H3K4me3 
on NCX3 gene (Fig.9). Moreover, the complex GATA3/KMT2A determines neuronal 
protection through the increase of NCX3 mRNA and protein expression, whose 
neurosurvival role has been demonstrated by several papers (Annunziato, Pignataro 
et al. 2004b; Secondo, Staiano et al. 2007; Formisano et al. 2008; Molinaro, Cuomo 
et al. 2008; Pignataro et al. 2011a; Pignataro et al. 2011b; Scorziello et al. 2013). 
Therefore, the development of drugs able to promote GATA3 and KMT2A up-
regulation, and thus to increase NCX3 expression, could represent a 
newpharmacological strategy in stroke intervention. 
 
 
  Fig 9 Transcriptional Complex Regulating ncx3 expression in Brain Ischemic Preconditioning 
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